1990

The Role of Urokinase Plasminogen Activator in Tumor Cell Metastasis

Heron Yu Cook
Loyola University Chicago

Recommended Citation
https://ecommons.luc.edu/luc_diss/2686

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1990 Heron Yu Cook
THE ROLE OF UROKINASE PLASMINOGEN ACTIVATOR IN TUMOR CELL METASTASIS

by

Heron Yu Cook

A Dissertation Submitted to the Faculty of the Graduate School of Loyola University of Chicago in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy

April

1990
DEDICATION

I wish to dedicate this dissertation to my family:

My husband, Chyung, who has offered me unselfish love, support, and understanding throughout the years.

My children, David and Lisa, who have kept me young, mature, and proud.

My parents, Chan-Jong and Iksoon Yu, who have believed in me by giving constant encouragement and support throughout my education.
ACKNOWLEDGMENTS

I am most grateful to my advisor, Dr. Richard Schultz, for his support and encouragement during my years of graduate school. Without his experience and guidance, this work could not have successfully been accomplished. I also would like to thank the members of my dissertation committee for their critical readings and discussions of this study.

I would like to give special thanks to Dr. Simone Silberman for her friendship and invaluable assistance with the animal studies and immunohistochemical work.

I also acknowledge the various contributions of my friends: Dr. Teresa Sestak for the reading of my dissertation; Mr. Kiril Raikoff for his help with animal surgery; Dr. Bruce Persky for the photography work.
Heron Yu Cook is the daughter of Chan-Jong Yu and Iksoon Kim Yu. She was born on September 3, 1950 in Seoul, Korea.

She obtained B.S. in chemistry at Yonsei University, Seoul, Korea in 1972. In the same year she came to the University of Kentucky, Lexington, KY, where she received a M.S. in Nutrition and Food Science in 1974.

She was employed at the University of Kentucky as a research technician for a year and moved to the Chicago area in the summer of 1975. From 1975 to 1976, she worked at G.D. Searle & Co. as a statistical coordinator in the Department of Statistics. From 1976 to 1980, she raised her children at home. For the next five years, she was employed as a research biochemist in the Section of Genetics at Rush Presbyterian St. Luke’s Medical Center studying protein-bound homocysteinuria. She was accepted to the Ph.D. program at Loyola University with a Basic Science Fellowship in 1985 and joined Dr. Schultz’s lab in 1987.
VITA (continued)

She is married to Chyung S. Cook, Ph.D. and has two children, David and Lisa. At the completion of her degree, she will pursue a Howard Hughes postdoctoral fellowship in Dr. Vikas Sukhatme's lab in the Department of Molecular Genetics and Cell Biology at the University of Chicago.
# TABLE OF CONTENTS

Dedication...........................................................................................................ii
Acknowledgments.........................................................................................iii
Vita................................................................................................................iv
List of Figures..............................................................................................xi
List of Tables..............................................................................................xiv
List of Abbreviations....................................................................................xvi

CHAPTER

I. Introduction.................................................................................................1

II. Review of the Literature............................................................................3

   Tumor Cell Metastasis..............................................................................3
   Proteases Involved in Tumor Cell Invasion........................................5
   Biochemistry of Urokinase.................................................................9
   Urokinase and Metastasis.................................................................15
   Urokinase Receptor..............................................................................20

III. Materials and Methods...........................................................................25

   Cell Culture.........................................................................................25
   pSV2-uPA Plasmid Construction.....................................................26
   pCLH3AXBPV-uPA Plasmid Construction.................................33
   pSV2-ASuPA Antisense Plasmid Construction..........................34
TABLE OF CONTENTS (continued)

III. Materials and Methods (continued)

<table>
<thead>
<tr>
<th>Assay</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA Transfection</td>
<td>45</td>
</tr>
<tr>
<td>Fibrin Overlay Assay</td>
<td>49</td>
</tr>
<tr>
<td>Filter Immunoblot Assay</td>
<td>50</td>
</tr>
<tr>
<td>Enzyme-Linked Immunosorbent Assay</td>
<td>52</td>
</tr>
<tr>
<td>Southern Blot Hybridization Analysis of pSV2-uPA Transfected Cells</td>
<td>54</td>
</tr>
<tr>
<td>Southern Blot Hybridization Analysis of pSV2-neo Transfected Cells</td>
<td>55</td>
</tr>
<tr>
<td>Southern Blot Hybridization Analysis of pRD2buktt Transfected Cells</td>
<td>56</td>
</tr>
<tr>
<td>Southern Blot Hybridization Analysis of pSV2-ASuPA Transfected Cells</td>
<td>57</td>
</tr>
<tr>
<td>Northern Blot Hybridization Analysis</td>
<td>57</td>
</tr>
<tr>
<td>Urokinase Receptor Binding Assay</td>
<td>59</td>
</tr>
<tr>
<td>125I Labeling of Human Urokinase</td>
<td>60</td>
</tr>
<tr>
<td>Concanavalin A Affinity Chromatography</td>
<td>61</td>
</tr>
<tr>
<td>Collection of Conditioned Medium</td>
<td>62</td>
</tr>
<tr>
<td>Fluorogenic Substrate Assay</td>
<td>63</td>
</tr>
<tr>
<td>Chromogenic Substrate Assay</td>
<td>64</td>
</tr>
<tr>
<td>125I-fibrin Plate Assay</td>
<td>65</td>
</tr>
</tbody>
</table>

vii
TABLE OF CONTENTS (continued)

III. Materials and Methods (continued)

Murine Lung Colonization Assay ................ 67
Spontaneous Metastasis Assay .................. 68
Culture of Lung Colony tumor Cells .......... 69
Cytotoxicity Assay ........................... 70
Statistical Analysis of Data .................... 71

IV. Results ........................................ 72

The Production of Human Urokinase in Murine B16-F1 Melanoma Cells and the Study of Its Effect on Tumor Cell Metastasis .................. 72

Expression of Human Preprourokinase Gene .................. 72

Characterization of Human Urokinase Produced by Murine Cells .................. 90

Determination of Urokinase Activity Urokinase .................. 94

In vivo Metastasis Assay ..................... 104

Demonstration of Human Urokinase in Murine Lung Tumor .................. 115

Inhibition of Urokinase Production in Murine B16-F10 Melanoma Cells and Study Its Effect on Lung Colonization .................. 118
TABLE OF CONTENTS (continued)

IV. Results (continued)

Inhibition of Urokinase Production in Murine B16-F10 Melanoma Cells and Study Its Effect on Lung Colonization (continued)........118

Expression of Antisense Human Urokinase Gene.................................118

Determination of Urokinase Production............................................121

Lung Colonization Assay.............................................................126

V. Discussion.................................................................137

Cell Lines Selected for the Study..............................................137

Expression of Human Urokinase Gene in B16-F1 Melanoma Cells...............138

Glycosylation of Human Urokinase by Murine Cells.................................140

Lack of Binding of Human Urokinase to Murine Receptor.............................141

Experimental Model for in vivo Metastasis Assay................................141

The Effect of Increased Expression of Urokinase on Lung Colonization Potentials....142

The Effect of Inhibition of Urokinase Production in the Lung Colonization Potential..........................154

ix
TABLE OF CONTENTS (continued)

VI. Summary..............................................160
References...............................................163
Appendix.................................................182
Approval Sheet

x
LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure No</th>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Structure of the plasmid pRdzbuktt</td>
<td>27</td>
</tr>
<tr>
<td>2</td>
<td>Construction of human preprourokinase expression vector pSV2-uPA</td>
<td>29</td>
</tr>
<tr>
<td>3</td>
<td>Structure of the plasmid pSV2-uPA</td>
<td>34</td>
</tr>
<tr>
<td>4</td>
<td>Structure of the plasmid pCLH3AXBPV</td>
<td>36</td>
</tr>
<tr>
<td>5</td>
<td>Construction of human preprourokinase expression vector pCLH3AXBPV-uPA</td>
<td>39</td>
</tr>
<tr>
<td>6</td>
<td>Structure of the plasmid pCLH3AXBPV-uPA</td>
<td>41</td>
</tr>
<tr>
<td>7</td>
<td>Construction of human preprourokinase antisense gene expression vector pSV2-ASuPA</td>
<td>43</td>
</tr>
<tr>
<td>8</td>
<td>Structure of the plasmid pSV2-ASuPA</td>
<td>46</td>
</tr>
<tr>
<td>9</td>
<td>Filter immunoblot analysis of transfected B16-F1 cell colonies</td>
<td>75</td>
</tr>
<tr>
<td>10</td>
<td>Southern blot hybridization analysis of DNA isolated from clone 7 of pSV2-uPA transfected B16-F1 and B16-F1 untransfected cells</td>
<td>79</td>
</tr>
<tr>
<td>11</td>
<td>Densitometer scan of autoradiographs of $^{32}$P hybridized to the genomic DNA of clone 7 or pSV2-uPA plasmid DNA</td>
<td>82</td>
</tr>
<tr>
<td>12</td>
<td>Northern blot hybridization analysis of RNA from clone 7 and 10 of pSV2-uPA transfected cell</td>
<td>85</td>
</tr>
<tr>
<td>Figure No</td>
<td>Content</td>
<td>Page</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>13</td>
<td>Densitometer scan of autoradiographs of $^{32}$P hybridized to the RNA of clone 7, 10 or pSV2-neo transfected cells</td>
<td>88</td>
</tr>
<tr>
<td>14</td>
<td>Concanavalin A affinity chromatography of human urokinase commercially purified preparation (A) and from pSV2-uPA transfected B16-F1 condition media (B)</td>
<td>92</td>
</tr>
<tr>
<td>15</td>
<td>Specific binding of human urokinase to human PC3-Met and murine B16-F1 cells</td>
<td>95</td>
</tr>
<tr>
<td>16</td>
<td>Secreted urokinase activity of B16-F1 and pSV2-uPA transfected B16-F1 cells as determined against a chromogenic substrate</td>
<td>97</td>
</tr>
<tr>
<td>17</td>
<td>Secreted urokinase activity of B16-F1 and pSV2-uPA transfected B16-F1 cells as determined by $^{125}$I-fibrin plate assay</td>
<td>101</td>
</tr>
<tr>
<td>18</td>
<td>Gross appearance of typical lungs dissected from control (left) and experimental (right) mice</td>
<td>110</td>
</tr>
<tr>
<td>19</td>
<td>Filter immunoblot analysis of transfected B16-F10 cell colonies</td>
<td>119</td>
</tr>
<tr>
<td>20</td>
<td>Secreted urokinase activity from B16-F10 and pSV2-ASuPA transfected B16-F10 cells determined by $^{125}$I-fibrin plate assay</td>
<td>123</td>
</tr>
<tr>
<td>Figure No</td>
<td>Content</td>
<td>Page</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>21</td>
<td>Southern blot hybridization analysis of antisense clone 10 and 8 of transfected B16-F10 cell DNA.</td>
<td>127</td>
</tr>
<tr>
<td>22</td>
<td>Gross appearance of typical lungs dissected from control (left) and experimental (right) mice.</td>
<td>131</td>
</tr>
<tr>
<td>23</td>
<td>Size of metastatic tumors in murine lung from mice tail-vein injected with B16-F10 transfected cells.</td>
<td>134</td>
</tr>
<tr>
<td>24</td>
<td>Southern blot hybridization analysis of DNA isolated from pSV2-neo and pRdzbuktt transfected cells to detect the pSV2-neo incorporation.</td>
<td>185</td>
</tr>
<tr>
<td>25</td>
<td>Southern blot hybridization analysis of DNA isolated from pSV2-neo and pRdzbuktt transfected cells to detect the pRdzbuktt incorporation.</td>
<td>187</td>
</tr>
<tr>
<td>26</td>
<td>Fibrin overlay assay to detect the transient expression of urokinase gene by the transfection of the plasmid pCLH3AXBPV-uPA to B16-F1 cells</td>
<td>191</td>
</tr>
</tbody>
</table>
**LIST OF TABLES**

<table>
<thead>
<tr>
<th>Table No.</th>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Quantification of human urokinase production by B16-F1 cells transfected with pSV2-uPA detected by ELISA</td>
<td>78</td>
</tr>
<tr>
<td>2</td>
<td>Quantification of secreted PA activity of B16-F1, B16-F10, and pSV2-uPA transfected B16-F1 cells by chromogenic substrate assay</td>
<td>100</td>
</tr>
<tr>
<td>3</td>
<td>Quantification of secreted PA activity of B16-F1, B16-F10, and pSV2-uPA transfected B16-F1 cells by 125I-fibrin plate assay</td>
<td>103</td>
</tr>
<tr>
<td>4</td>
<td>Quantification of secreted PA activity of pSV2-uPA transfected B16-F1 cells by chromogenic substrate assay</td>
<td>105</td>
</tr>
<tr>
<td>5</td>
<td>Lung colonization by B16-F1 murine melanoma cells transfected with human preprourokinase cDNA in a SV40 expression vector</td>
<td>107</td>
</tr>
<tr>
<td>6</td>
<td>Lung colonization by B16-F1 murine melanoma cells transfected with pSV2-neo and pSV2-uPA (clone 8 and 12)</td>
<td>109</td>
</tr>
<tr>
<td>7</td>
<td>Color distribution of metastatic tumors in murine lung from mice tail-vein injected with B16-F1 transfected cells</td>
<td>113</td>
</tr>
<tr>
<td>8</td>
<td>Spontaneous pulmonary metastasis by B16-F1 murine melanoma cells transfected with human preprourokinase cDNA in a SV40 expression vector</td>
<td>114</td>
</tr>
<tr>
<td>Table No.</td>
<td>Content</td>
<td>Page</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>9</td>
<td>Quantification of human Urokinase production by B16-F1 transfected cells and the same cells passaged through animal by ELISA</td>
<td>116</td>
</tr>
<tr>
<td>10</td>
<td>Quantification of plasminogen activator production by B16-F1 transfected cells and the same cells passaged through animal by chromogenic substrate assay</td>
<td>117</td>
</tr>
<tr>
<td>11</td>
<td>Quantification of secreted urokinase activity from B16-F10 transfected cells by chromogenic substrate assay</td>
<td>122</td>
</tr>
<tr>
<td>12</td>
<td>Quantification of secreted urokinase activity of B16-F10 and transfected B16-F10 cells as determined by $^{125}$I-fibrin plate assay</td>
<td>125</td>
</tr>
<tr>
<td>13</td>
<td>Lung colonization by B16-F10 murine melanoma cells transfected with human preprourokinase antisense gene in a SV40 expression vector</td>
<td>130</td>
</tr>
<tr>
<td>14</td>
<td>Size of metastatic tumors in murine lung from mice tail-vein injected with B16-F10 transfected cells</td>
<td>136</td>
</tr>
<tr>
<td>15</td>
<td>Quantification of plasminogen activator production of B16-F1 cells transfected with pRdzbuktt by fluorogenic substrate assay</td>
<td>189</td>
</tr>
</tbody>
</table>
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AS DNA</td>
<td>antisense DNA</td>
</tr>
<tr>
<td>ASuPA</td>
<td>antisense urokinase plasminogen activator</td>
</tr>
<tr>
<td>BCIP/NBT</td>
<td>5-bromo-4-chloro-3-indoyl phosphate/nitroblue tetrazolium</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>CAM</td>
<td>chorioallantoic membrane</td>
</tr>
<tr>
<td>cAMP</td>
<td>cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>ConA</td>
<td>concanavalin A</td>
</tr>
<tr>
<td>DFP</td>
<td>diisopropyl fluorophosphate</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's Modified Eagle's Medium</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediamine tetraacetic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FBS</td>
<td>fetal bovine serum</td>
</tr>
<tr>
<td>HBSP</td>
<td>HEPES-buffered saline phosphate</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid</td>
</tr>
<tr>
<td>MEM</td>
<td>Eagle's minimum essential medium</td>
</tr>
<tr>
<td>PA</td>
<td>plasminogen activator</td>
</tr>
<tr>
<td>PAI</td>
<td>plasminogen activator inhibitor</td>
</tr>
<tr>
<td>PBS</td>
<td>phosphate buffered saline, pH 7.4</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>PMA</td>
<td>phorbol myristate acetate</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodesyl sulfate</td>
</tr>
<tr>
<td>SSPE</td>
<td>saline sodium phosphate EDTA</td>
</tr>
<tr>
<td>SFM</td>
<td>serum free medium</td>
</tr>
<tr>
<td>SSC</td>
<td>standard saline citrate</td>
</tr>
<tr>
<td>TE</td>
<td>Tris-EDTA buffer</td>
</tr>
<tr>
<td>TIMP</td>
<td>tissue inhibitor of metalloproteinases</td>
</tr>
<tr>
<td>tPA</td>
<td>tissue type plasminogen activator</td>
</tr>
<tr>
<td>uPA</td>
<td>urokinase type plasminogen activator</td>
</tr>
</tbody>
</table>
Chapter I

INTRODUCTION

Activation of plasminogen to plasmin by urokinase plasminogen activator may play an essential role in tumor cell invasion and metastasis. Plasmin is capable of digesting the extracellular matrix and basement membrane. It exerts its proteolytic action either directly by degrading glycoproteins, such as laminin, fibronectin and proteoglycans or indirectly by activating procollagenases to collagenases. Collagenases which degrade collagen, a major structural protein of basement membrane, are believed to contribute to the ability of a tumor cell to metastasize. Therefore it has been suggested that urokinase plasminogen activator might be the essential proteolytic enzyme to initiate the cascade of protease activation that results in tumor cell invasion and metastasis.

The goal of this dissertation was to study the role of urokinase plasminogen activator in the metastatic
process by a direct approach at the gene level. This study was carried out by increasing the production of urokinase activity or inhibiting endogenous urokinase production by means of the urokinase gene modification in tumor cells and testing the metastatic potential of the modified cells.

The results of this study may address the role of the secreted form of urokinase in the later steps of the metastatic process as well as in the full metastatic process.
Chapter II

REVIEW OF THE LITERATURE

Tumor Cell Metastasis

Tumor cell metastasis is a transfer of malignant tumor cells from the primary site of tumor formation to distant organs, and is the major cause of cancer deaths. The metastasis of tumor cells is a complex process which involves multiple steps.

At the first step of metastasis, primary tumor cells invade through the extracellular matrix and basement membrane, spread into adjacent normal tissue, intravasate through the capillary endothelial walls, and are eventually released into the circulation. Few tumor cells survive the transit through the circulation. Those tumor cells that do survive arrest in the capillary beds of distant organs and extravasate from the capillaries through the basement membrane and extracellular matrix into the surrounding normal tissue. At the final step of metastasis, the extravasated tumor cells grow and give
rise to secondary tumor deposits.

During the intravasation and extravasation steps, tumor cells must invade a variety of extracellular matrices and basement membranes in order to enter the underlying interstitial stroma. The extracellular matrix is composed of a dense lattice of interstitial collagens and elastin fibers embedded within a ground substance consisting of fibronectin, other glycoproteins, and proteoglycans. The basement membrane is composed of type IV collagen, laminin, other specific glycoproteins, and heparan sulfate proteoglycans.

A three-step theory has been proposed by Liotta et al. (1986) to explain the sequence of tumor cell invasion to the extracellular matrix. The first step is tumor cell attachment to the matrix by cell surface receptors that specifically bind components of the matrix, such as laminin. Laminin forms a bridge between the cell surface laminin receptor and type IV collagen in the basement membrane. The second step of tumor cell invasion is the local degradation of the matrix by proteolytic enzymes. These are produced by tumor cells or host cells that have been induced by tumor cells. The third step is the tumor cell locomotion into the region of matrix modified by the proteolytic enzymes. Thus the degradation of the above
tissue barrier by proteolytic enzymes is a part of the key step of tumor cell invasion and, in turn, metastasis.

**proteases Involved in Tumor Cell Invasion**

Due to the complexity of the tissue barriers that tumor cells must cross in the invasion process, the degradation of the matrix may require several proteolytic enzymes. The proteolytic enzymes, which have been implicated in this step are collagenases, particularly type IV, endoglycosidases, cathepsin B-like thiol proteinases, and plasminogen activators (Nicolson, 1982).

A cathepsin B-like proteinase can degrade several components of the extracellular matrix such as denatured collagen, fibronectin and proteoglycan (Sloane and Honn, 1984). In addition, it has been suggested that cathepsin B-like proteinase might have the potential to activate latent type IV collagenase (Sloane et al., 1986). Increased amounts of cathepsin B-like thiol proteinase have been found in solid tumors (Poole et al., 1980; Recklies et al., 1980; Rinderknecht and Renner, 1980; Ryan et al., 1985), transformed cell (Myra-y-Loopeze et al., 1985), and tumor cells in culture (Sloan et al., 1981; Sloane et al., 1982; Ryan et al., 1984). However, there
are contradictory results which do not find any correlation between cathepsin B-like activity and metastatic potential (McLaughlin et al., 1983). Others have reported that cathepsin B-like activity is negatively correlated with transformation (Dolbeare et al., 1980; Morgan et al., 1981). Inhibitors of cathepsin B placed in high steady-state concentrations within an animal model for metastasis failed to show any inhibition of metastasis (Ostrawski et al., 1986).

Endoglycosidases cleave heparan sulfate from matrix proteoglycans. Heparan sulfate interacts with matrix macromolecules, such as collagens and fibronectin, and plasma membrane attachment sites. Therefore, endoglycosidases have also been shown to be involved in tumor invasion and metastasis (reviewed by Goldfarb and Liotta, 1986).

Interstitial collagenases hydrolyze collagen types I, II, and III of the extracellular matrix. Several investigators reported a positive correlation between tumor cell secretion of interstitial collagenase by mouse primary tumor cells and lung metastasis (Tarin et al., 1982). Another study showed the invasion of a chick chorioallantoic membrane by human choriocarcinoma cell lines correlated well with the production of collagenase
but did not correlate with secretion of plasminogen activator or cathepsin B (Sekiya et al., 1985).

The major structural protein of basement membrane, type IV collagen, is not degraded by the interstitial collagenase, but by type IV collagenase (Salo et al., 1982). Type IV collagenase is secreted in a latent form and shown to be activated by plasmin in vitro (Werb et al., 1977; Paranjpe et al., 1980; Gross et al., 1982; He et al., 1989). Enhanced levels of type IV collagenase has been shown in malignant tumor cells (Liotta et al., 1986; Goldfarb et al., 1986). Positive correlation between type IV collagenase activity and the pulmonary metastatic potential has been demonstrated in B16 melanoma cell lines (Liotta et al., 1980) and breast cancer cell lines (Nakajima et al., 1986).

Plasminogen activator (PA) is a serine protease which converts the inactive proenzyme plasminogen to plasmin. The plasminogen, is ubiquitous in the blood and tissue spaces. Plasmin can degrade many components of the extracellular matrix in vitro such as proteoglycans (Mochan and Keler, 1984), fibronectin (Liotta et al., 1981; Kramer et al., 1982), and laminin (Liotta et al., 1981; Boyd et al., 1989). Plasmin has also been shown to activate procollagenase to collagenase in vitro, including
type IV collagenase, which degrades type IV collagen (Werb et al., 1977; Paranjpe et al., 1980; Gross et al., 1982; He et al. 1989). Therefore, plasminogen activator, via activation of plasminogen, may have a central role in initiating cascade reactions that degrade the molecules composing the barriers which tumor cells must cross during metastasis. The details of plasminogen activator activity in tumor cell metastasis will be discussed separately.

Two distinct types of plasminogen activators are known, tissue-type plasminogen activator and urokinase type. They are genetically and immunologically distinct forms. The two proteins have different amino acid sequences, molecular weights, subunit structures and catalytic parameters such as affinity to fibrin. Tissue-type plasminogen activator is released from the endothelial cells of the blood vessels and urokinase-type plasminogen activator is synthesized in kidney cells and released from the renal tubules. Immunological characterization has shown that most tumor cells produce urokinase-type plasminogen activator rather than tissue-type (reviewed by Dano et al., 1985). There are some exceptions where tissue-type plasminogen activator was demonstrated in breast tumor cells induced by carcinogens, in melanoma cells (Dano et al., 1985), and several other
tumor cell lines (Quax et al., 1990). In general though
tissue-type plasminogen activator appears to be involved
in fibrinolytic function of the cell, such as lysis of
fibrin clots, and urokinase-type activity is involved in
cell migration and tumor cell metastasis.

In this report, the term "plasminogen activator" is
used when unable to identify which type of activator is
being studied. The term "urokinase" is used when the
basis of its origin is from the urokinase plasminogen
activator identified by the urokinase plasminogen
activator gene or evaluated by immunological assays.
Tissue-type plasminogen activator is referred to as
"tissue PA".

Biochemistry of Urokinase

The urokinase gene has been isolated and sequenced
from human (Heyneker et al., 1983; Riccio et al., 1985;
Nagai et al., 1985), mouse (Degen et al., 1987), pig
(Nagamine et al., 1985), and chicken (Leslie et al.,
1990). Comparison of the human urokinase gene and the
porcine, murine, or chicken gene has shown an extensive
homology (72-79% nucleotide sequence identity) throughout
the introns and exons (Degen et al., 1987). The four
urokinase genes are also similar in size: human, 6388 base pairs; porcine, 5852 base pairs; murine, 6710 base pairs; and chicken, 8158 base pairs (Degen et al., 1987). The human urokinase gene is located on the long arm of chromosome 10 (Tripputi et al., 1985), while human tissue PA is on chromosome 8 (Blasi et al., 1986). The human urokinase gene consists of 11 exons and 10 introns (Riccio et al., 1985). The mRNA of human urokinase is shown to be 2.5 Kb and the cDNA is composed of 1293 base pairs (Verde et al., 1984). Human urokinase is a glycoprotein (Holmes et al., 1985; Ricco et al., 1985) while mouse urokinase contains no N-glycosylation site (Belin et al., 1985).

Urokinase is synthesized as a single-chain preprourokinase composed of 431 amino acids as shown by its cDNA size and has a molecular weight of 54 Kd (Salerno et al., 1984). It contains a signal leader sequence of 20 amino acids which is removed during protein synthesis (Pennica et al., 1983). Urokinase is secreted as an inactive single-chain prourokinase zymogen of 411 residues. However, some investigators reported that prourokinase purified from certain cell lines demonstrated catalytic activity (Stumpt et al., 1986; Ellis et al., 1987). The single-chain prourokinase is activated by a proteolytic cleavage which removes one amino acid, lysine,
at position 158. Thus the activation generates a two-chain urokinase molecule (A-chain and B-chain) held together by one disulfide bond (Gunzler et al., 1982). The activation is mediated by many compounds such as plasmin (Dano et al., 1985), plasma kallikrein (Ichinose et al., 1986), factor XIIa (Ichinose et al., 1986), trypsin (Eaton et al., 1984), and thrombin (Eaton et al., 1984). Plasmin appears to be the most efficient activator (Eaton et al., 1984; Ichinose et al., 1986). At certain concentrations, thrombin has been found to inactivate prourokinase by cleaving arg-156 and phe-157 (van Hinsbergh et al., 1987). The active urokinase can be further cleaved by plasmin to form a still active 33 Kd molecule (Stump et al., 1986). Whether the 33 Kd urokinase has specific function is not known.

Urokinase consists of five distinctive domains, known as the signal domain, growth factor domain, kringle domain, connecting domain, and catalytic domain (Verde et al., 1984). The growth domain is homologous to epidermal growth factor, alpha transforming growth factor, coagulation factors IX and X, and prothrombin (Anson et al., 1984; Fernlund et al., 1982). The homology to growth factors might suggest a growth promoting activity of urokinase in certain cell lines (Kirchheimer et al.,
1987). The kringle domain is also present in other zymogens, such as prothrombin (Magnusson et al., 1976) and plasminogen (Sottrup-Jensen et al., 1978). The catalytic domain carries the typical active site of the serine proteases. Comparison of the amino acid sequence of tissue PA and urokinase shows that two domains of the tissue PA are missing in urokinase. The first missing domain is the finger-like domain which may be responsible for the high affinity of tissue PA for fibrin (Banyai et al., 1983) and explains the greater fibrinolytic effect of tissue PA than of urokinase. The second missing domain in urokinase is the second kringle domain of tissue PA.

The production of urokinase is affected by several compounds such as hormones, growth factors, cAMP, and tumor promoters. It was shown that calcitonin and vasopressin in porcine kidney cells (Nagamine et al., 1983) and estrogen in breast carcinoma cells (Mira-y-Lopez and Ossowski, 1987) induced urokinase mRNA expression. Glucocorticoid has been shown to depress the expression of urokinase activity in cultured cells (Busso et al., 1987). Dexamethasone also decreased the urokinase mRNA levels in normal and several malignant tumor cells (Medcalf et al., 1986). Growth factors, such as epidermal growth factor (EGF) (Boyd, 1989; Niedbala and Sartorelli, 1989),
platelet-derived growth factor (PDGF) (Stoppelli et al., 1986), and interferon (IFN-gamma) (Collart et al., 1986) increased the levels of urokinase mRNA in cultured cancer cells. Transforming growth factor beta gave dual effects, in that it stimulated urokinase secretion in certain malignant cell lines (Keski-Oja et al., 1988) and it decreased the secretion of urokinase in bovine endothelial cells (Saksela et al., 1987). The transcriptional increase of urokinase by hormone or growth factor is mediated through the cAMP pathway (Saksela and Rifkin, 1988). The 5'-nontranscribed regions of murine, porcine, and human urokinase genes were found to contain dodecanucleotides homologous to cAMP regulatory sequences (Degen et al., 1987; Riccio et al., 1985; Nagamine et al., 1985). The tumor promoter, phorbol myristate acetate (PMA) also increased urokinase mRNA synthesis in various carcinoma cells (Kelly et al., 1983; Degen et al., 1985; Collart et al., 1986), transformed cells (Belin et al., 1984), and chicken embryo fibroblasts (Bell et al., 1990). The increase of urokinase mRNA level by PMA stimulation was parallel to the increase of c-myc transcription (Stoppelli et al., 1986). The increase occurred within 30 minutes and peaked 2-4 hour after the PMA treatment (Stoppelli et al., 1986).
The regulation of urokinase activity is also modulated by the urokinase specific cell surface receptor. Another regulatory mechanism for urokinase activity is the secretion of plasminogen activator inhibitors (PAIs). Three of the inhibitors, PAI-1, PAI-2, and protease nexin are reported to regulate plasminogen activator activity by rapid inhibition in vivo (Saksela and Rifkin, 1988).

Urokinase can regulate a variety of physiological events that require extracellular proteolysis, such as fibrin clot lysis, tissue remodeling, and cell migration (reviewed by Dano et al., 1985). Proteolytic degradation of extracellular matrix components starts with activation of plasminogen by plasminogen activator, subsequently the formation of plasmin, and activation of procollagenase to collagenase by plasmin as discussed previously. Involvement of urokinase in cell migration is observed in vitro. It was shown that the continuously migrating, wounded endothelial cells have increased urokinase activity (Pepper et al., 1987). Another physiological process involving urokinase may be angiogenesis. Urokinase has a function in the formation of new blood vessels supplying the newly formed tumor with nutrients required for rapid growth (d'Amore, 1988; Goldfarb et al., 1986). Lastly, urokinase may be involved in ovulation.
Hormones associated with ovulation such as follicle stimulating hormone (FSH) and luteinizing hormone (LH), stimulate plasminogen activator (Ny et al., 1985; Canipari et al., 1987). The regulation of urokinase activity is also shown in pathological processes such as inflammation, pemphigus, cancer, and metastasis (Dano et al., 1985).

**Urokinase and Tumor Cell Metastasis**

Indirect evidence in support of a role for urokinase in metastasis has been shown by multiple studies and is reviewed by Dano et al. (1985). An increase in urokinase gene expression or an enhanced urokinase synthesis/secretion have been observed in metastatic variant cell lines such as lung and breast carcinomas (Sappino et al., 1987), mammary adenocarcinomas (Ramshaw et al., 1986; Pereyra-Alfonso et al., 1988; Burtin et al., 1987), Lewis lung carcinoma (Eisenbach et al., 1985), mammary carcinoma (Pauli et al., 1987), human malignant melanoma (Markus et al., 1984), and murine fibrosarcoma (Nagy and Grdina, 1989). Furthermore, many of the solid tumors of lung (Markus et al., 1980), prostate (Kirchheimer et al., 1985; Camiolo et al., 1987; Gaylis et al., 1989), breast (Duffy et al., 1988), stomach (Szczepanski et al., 1982),
digestive tract (Noshino et al., 1988), and colon (de Bruin et al., 1987) showed increased secretion of urokinase as compared to their untransformed counterparts. Treatment of cells with tumor promoters (Degen et al., 1985; Stoppelli et al., 1986), tumor viruses (Unkeless et al., 1973, Skriver et al., 1982), and src oncogene product (Bell et al., 1990) also increased the gene expression or enhanced the secretion of urokinase from cells in vitro.

There have been a number of studies that show a correlation between plasminogen activator production and metastasis in murine B16 melanoma cell lines. Carlsen et al. (1984) isolated clonal tumor cell populations which produced various levels of plasminogen activator activity and determined the metastatic potential of the isolated clones by a lung colonization assay. Their results showed a strong correlation between production of plasminogen activator activity and metastatic potential. Wang et al. (1980) also demonstrated that murine B16-F10 cells, a highly metastatic subline of the B16 cell line, produced a significantly greater amount of plasminogen activator activity than the B16-F1 subline of lower metastatic potential. This result, however, is in contrast to the work of Nicolson et al. (1976) who found that there was essentially no difference in plasminogen activator
activity between B16 variant cell lines.

A recent study showed that transfected mouse L cells expressing the human urokinase gene demonstrated an increased degradation of extracellular matrix protein and invasion of a Matrigel basement membrane. This work indicated that urokinase expression may be sufficient to provide an invasive phenotype in the cell (Cajot et al., 1989).

Immunocytochemical studies have also been used to indicate the importance of urokinase activity in tumor cell metastasis (Pollanen et al., 1987). Skriver et al. (1984) reported an increased urokinase level by means of immunohistochemical staining in areas close to or in contact with normal cells of the surrounding tissue being invaded by the tumor cells.

Since type IV collagen is a major constituent of basement membrane, it has been considered as an important substrate for tumor invasion. Type IV collagenase, which is activated from procollagenase by plasmin, degrades type IV and type V collagen and is therefore believed to have an important role in the invasion of tumor cells through the extracellular matrix and basement membrane (Liotta et al., 1980; Goldfarb and Liotta, 1986; Reich et al., 1988; Schultz et al., 1988).
The human tissue inhibitor metalloproteinase (TIMP), a glycoprotein with a molecular weight of 28,000, is an inhibitor of metalloproteinases such as type I collagenase, type IV collagenase, and stromelysin. TIMP has been shown to inhibit lung colonization by B16-F10 cells in vivo (Schultz et al., 1988). Similar results were reported with a synthetic collagenase inhibitor that reduced the lung lesion in the same system (Reich et al., 1988). In addition, Khokha et al. (1988) found that transfection of an antisense RNA, complementary to the mRNA encoding the collagenase inhibitor (TIMP), changed the non-metastatic and non-tumorigenic mouse 3T3 fibroblasts, to the metastatic and tumorigenic phenotype that has the ability to colonize the lungs of nude mice.

Whereas the majority of reports support a positive correlation between metastatic potential and urokinase activity, there exist other reports which show a lack of such a correlation. One report stressed that the only proteinase secreted by malignant tissue was the cathepsin B-like thiol proteinase (Rechlies et al., 1980). Others reported a decreased plasminogen activator activity in the plasma of tumor-bearing patients compared to normal subjects (Colombi et al., 1984). Another study reported that plasminogen activator was enriched in the tumor cell
membranes, however serine inhibitors did not abrogate collagenolytic activity (Zucker et al., 1985).

One of the questions regarding the possible role of urokinase in the metastatic process is whether urokinase activity is required in the early steps such as intravasation or during the later steps such as extravasation. Earlier work of Ossowski and Reich (1983) showed that the injection of an antibody to urokinase into the chick embryo prevented cells, which were placed on the chorioallantoic membrane, from metastasizing to the embryonic lung. However, if the human HEp2 tumor cells were placed directly into a vein, the urokinase antibody had no inhibitory effect on lung colonization (Ossowski, 1988). These results may indicate that urokinase is only required for the intravasation step into the blood vessels, but not for extravasation out of the blood vessels (Ossowski, 1988).

Contrary to this, several other studies reported that an increase in urokinase activity is correlated with increased lung colonization following i.v. injection, urokinase therefore plays a causal role in the extravasation step of the metastatic cascade. Hearing et al. (1988) showed that B16 cells pretreated with antibody to urokinase on their cell surfaces showed decreased
numbers of metastases and that pretreatment of B16-F10 cells with plasmin, which converts single chain urokinase to the more active two chain form of urokinase, increased the numbers of metastases in the lung colonization assay. Very recently, Axelrod et al. (1989) expressed the urokinase gene in H-ras-transformed NIH3T3 cells by transfection of recombinant gene, and found that the increase in urokinase gene expression resulted in a large increase in pulmonary metastasis following tail vein injection in nude mice. Also Brunner et al. (1989) reported that mouse bladder carcinoma cells transfected by Ha-ras cells produced a 3-fold increase in urokinase activity in cell lysates and 3-fold increase in cell surface-associated urokinase activity. This particular clone induced a 6-fold increase in lung colonies.

**Urokinase Receptor**

A specific cell surface receptor with high affinity for urokinase has been first identified in human blood monocytes (Vassalli et al., 1985) and is present on a variety of normal cells, such as fibroblasts, endothelial cells, granulocytes, spermatozoa, and a number of malignant tumor cells (Testa and Quigley, 1988; Stoppelli
et al., 1986; Vasaalli et al., 1985). It has been purified from several cell lines (Needham et al., 1987; Nielsen et al., 1988; Estreicher et al., 1989). The receptor appears to be a 55-60 Kd glycoprotein (Nielsen et al., 1988). The number of receptors on cells, such as monocytes or fibroblasts is about $10^5$ sites per cell (Blasi et al., 1986). The urokinase receptor binds to the amino terminal fragment (ATF) of the single chain form of prourokinase or to the two chain form of urokinase (Stoppelli et al., 1985). More precisely it binds within the first 32 residues of the growth factor domain in urokinase (Appellal et al., 1987). Therefore, the binding of urokinase is completely independent of the catalytic domain which is located in carboxyl terminal of the urokinase molecule (Stoppelli et al., 1985; Appella et al., 1987). The 33 Kd urokinase, generated by plasmin from the 54 Kd urokinase, does not bind to the receptor (Needham et al., 1987).

It has been reported by immunofluorescence, immunoprecipitation, and surface iodination assays that the same cells have both secreted and membrane associated urokinase activities (Stoppelli et al., 1986). This suggests that prourokinase might be initially secreted into the extracellular space with subsequent binding to
the specific receptor via an autocrine mechanism. When bound to its specific receptor, urokinase is not internalized so its enzymatic activity is retained. Mild acid treatment releases the receptor bound urokinase from the cell surface (Stoppelli et al., 1986).

The binding of urokinase to its cellular receptor is shown to be extremely specific. Any other related proteins, such as epidermal growth factor (EGF), factor IX and X, tissue PA, plasminogen, and thrombin do not compete for binding with the amino terminal fragment (ATF) of urokinase or with high molecular weight urokinase (Blasi et al., 1986; Blasi, 1988). Urokinase binding also shows species specificity (Stoppelli et al., 1986; Estreicher et al., 1989). Murine urokinase binds to murine sperm cells but not to human cells (Huarte et al., 1987).

The binding of urokinase to its receptor is shown to be increased by epidermal growth factor (EGF) treatment of the carcinoma cells (Blasi et al., 1986; Boyd, 1989). Phorbol myristate acetate (PMA) has been shown to increase urokinase receptor synthesis in a time and concentration dependent manner. PMA treatment also caused a decrease in affinity of the urokinase receptor, suggesting another way of regulating the interaction between urokinase and its receptors (Picone et al., 1988).
The function of the urokinase receptor has not been established, however, possible advantages have been suggested. First, since the carboxyl terminal domain remains exposed on the cell surface upon receptor binding, urokinase binding might stimulate localized proteolytic activity (Stoppelli et al., 1985; Pollanen et al., 1990). Secondly, the receptor bound enzyme might be protected from inactivation by inhibitors. It has been shown that plasmin generated from the cell bound plasminogen is less susceptible to inhibitors than its fluid phase counterpart (Plow et al., 1986). Thirdly, the binding of urokinase to the cell surface might concentrate other substrates of the multistep pathway, and subsequently increase the rate of the cascade reaction (Moscatelli and Rifkin, 1988).

A possible role of urokinase binding to the receptor has been shown by several investigators. As stated earlier, urokinase has a growth factor domain in its amino acid sequence (Verde et al., 1984) which might provide the mitogenic activity of urokinase. The binding of urokinase to its receptor seems to be necessary for the growth stimulation of certain cell lines. It was demonstrated that the 54-Kd urokinase which binds to its receptors stimulated the growth and proliferation of human epidermal cells (Kirchheimer et al., 1989) and uterine and
ovarian cancer cells (Takada and Takada, 1989), whereas the 33-Kd urokinase fragment, which lacks the growth factor domain and contains only the active-site domain, did not stimulate cell proliferation (Kirchheimer et al., 1989).

A question regarding the role of urokinase in metastasis concerns its possible location of action. Recent work has shown that many tumor cells contain urokinase receptors on their cell surfaces (Needham et al., 1987; Stoppelli et al., 1986). Likewise, an increase in cell surface urokinase receptor has been correlated with an increased metastatic potential (Boyd et al., 1988). In vivo invasion assays with chick embryo chorioallantoic membrane (CAM) showed that the invasive ability of human tumor cells was augmented by saturating their receptors with exogenous urokinase. The stimulation of urokinase production in the absence of binding to cell receptors did not enhance invasiveness (Ossowski, 1988).

Boyd et al. (1988) determined the levels of urokinase and its receptor in colon carcinoma cell lines of different differentiation degrees, and found aggressive metastatic cell lines expressed a higher number of receptors and a higher level of secreted endogenous urokinase activity than more indolent cell lines.
Chapter III

MATERIALS AND METHODS

Cell Culture

The B16-F1 and B16-F10 cells (Fidler, 1975) were kindly provided by Dr. I.J. Fidler, M.D. Anderson Medical Center, University of Texas, Houston, TX. Cells were grown in Eagle's minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Flow Laboratory, McLean, VA), 1% MEM nonessential amino acids (Gibco Laboratories, Grand Island, NY), 1 mM sodium pyruvate, 1% MEM vitamin solution (Gibco Laboratories), 75 units/ml of penicillin and 75 ug/ml of streptomycin sulfate (Gibco Laboratories). Cells were incubated at 37 C in 5% CO_2 saturated with water vapor and were maintained by changing the medium every three days and subculturing at a 1:3 ratio at confluence. For the subculture, cells were detached from the flasks by incubation with 1 mM ethylenediamine tetracetic acid (EDTA) in phosphate buffered saline (PBS) for several
minutes. The total number of viable cells were determined by trypan blue exclusion in a hemocytometer (C.A. Hausser and Son, Philadelphia, PA).

**pSV2-uPA Plasmid Construction**

The plasmid pSV2-uPA containing the human preprourokinase plasminogen activator coding sequences in the sense direction was made from two plasmids, pSV2-dhfr and pRdzbuktt. pSV2-dhfr was purchased from American Tissue Culture Center, Rockville, Md. and pRdzbuktt was a gift of Dr. Michael E. Reff, Smith Kline & French & Co., King of Prussia, PA. The plasmid pRdzbuktt is a mammalian expression vector containing the full length cDNA for human preprourokinase, Rous sarcoma virus (RSV) long terminal repeats (LTR) promoter, a bovine growth hormone (BGH) polyadenylation signal, the dihydrofolate reductase (dhfr) terminator, the pBR322 origin of replication, and an ampicillin resistant gene (Figure 1). pSV2-dhfr is a mammalian expression vector containing the dihydrofolate reductase (dhfr) gene, a SV40 early and late gene promoters, a SV40 polyadenylation signal, the pBR322 origin of replication, and an ampicillin resistant gene. The strategy of plasmid construction, as shown in Figure 2, was to replace the dihydrofolate reductase (dhfr) gene
Figure 1. Structure of the plasmid pRdzbuktt

The plasmid pRdzbuktt contains the full length cDNA for human preprourokinase, Rous sarcoma virus (RSV) long terminal repeats (LTR) promoter, a bovine growth hormone (BGH) polyadenylation signal, the dihydrofolate reductase (dhfr) terminator, the pBR322 origin of replication, and an ampicillin resistant gene. The human preprourokinase gene can be retrieved from the plasmid by digestion with HindIII and SacI. The transcription is clockwise in the 5' to 3' direction. Restriction enzymes with unique recognition sites are shown on the map.
Figure 2. Construction of human preprourokinase expression vector pSV2-uPA containing SV40 early gene promoter

The human 1021 base pair preprourokinase cDNA gene (uPA) was obtained by digestion of plasmid pRdzbuktt with SacI and HindIII. Plasmid pSV2-dhfr was digested with HindIII and BglII to remove the dhfr gene. The uPA sequence was ligated to the large fragment (4249 base pairs) of the pSV2 plasmid to make the pSV2-uPA expression plasmid containing human preprourokinase gene in a sense direction with respect to the SV40 early gene promoter. Transcription is clockwise in the 5' to 3' direction. The protein coding sequences are shown in hatched area.
pSV2-dhfr

pBR322 ori

SV40-ori

HindIII

BglII

dhfr

SV40-L

SV40-E

pSV2-dhfr

pBR322 ori

amp^R

SV40-ori

HindIII

BglII

dhfr terminator

pRdzbuktt

amp^R

RousLTR

HindIII

uPA

HindIII+BglII

SacI+HindIII

DNA polymerase I + dNTPs
DNA ligase

amp^R

PBR322 ori

SV40-E

pSV2-uPA

SV40-ori

uPA
of pSV2-dhfr with the preprourokinase gene of pRdzbuktt in
the sense orientation relative to the SV40 early gene
promoter. In order to remove the dhfr gene from pSV2-
dhfr, the pSV2-dhfr was digested with HindIII and BglII.
Both cohesive ends were repaired to give blunt ends by
incubation with 5 units of T4 DNA polymerase I (Boehringer
Mannheim Biochemicals, Indianapolis, IN) and 0.5 mM of the
mixture of dATP, dGTP, dCTP, TTP (Sigma Chemical Co.) in
an assay buffer provided by the manufacturer, at 37°C for
30 minutes. The repaired DNAs were then treated with 10
units of alkaline phosphatase from calf intestine
(Boehringer Mannheim Biochemicals) to prevent self
ligation, by incubation for 1 hour at 50°C in the assay
buffer. The repaired DNA fragments were separated by
electrophoresis in 0.8% agarose gel. The 4249 base pairs
of large fragment DNA which contains the entire pSV2-dhfr
sequences, except for the dhfr gene, was eluted from
agarose gel using the IBI Analytical Electroeluter
(International Biotechnologies Inc., New Haven, CT).

To isolate the human preprourokinase cDNA from the
plasmid pRdzbuktt, the pRdzbuktt was digested with HindIII
and SacI, blunt ended as described previously for pSV2
vector, and separated by electrophoresis. The small
fragment DNA of pRdzbuktt which contains 1021 base pairs
corresponding to the preprourokinase coding sequences was eluted. The pSV2-vector fragment and human preprourokinase fragment, were ligated overnight at room temperature by 2 units of T4 DNA ligase (IBI, New Haven, CT) in the assay buffer provided by the manufacturer. The ligated DNA was then transformed in E-coli strain HB101. prior to transformation, the E-coli was cultured in SOB medium (2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄), resuspended in RF1 buffer (100mM RbCl, 50 mM MnCl₂, 30 mM potassium acetate, 10mM CaCl₂.2H₂O and 15% glycerol), then in RF2 buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaCl₂.2H₂, 15% glycerol) to improve transformation efficiency (Hanahan, 1983). Ampicillin resistant clones were selected and grown in LB medium with 50 ug/ml of ampicillin.

Plasmid DNAs of selected clones were screened for the insertion of the preprourokinase gene by restriction endonuclease digestion with BglII and were rescreened for the pSV2-uPA in the sense orientation by restriction endonuclease digestions with BamHI, PstI, and PvuII. The clone with the correct digestion fragments for pSV2-uPA were amplified in the presence of chloroamphenicol (170 ug/ml). The plasmid DNA from the selected clone was prepared in large scale by the lysis of the E-coli cell
wall with 0.2 N NaOH/1% SDS and plasmid DNA extraction with isopropanol. The prepared DNA was purified by centrifugation to equilibrium in cesium chloride-ethium bromide density gradient (Maniatis et al., 1982) for transfection. The plasmid structure and the restriction digestion map of the constructed pSV2-uPA is shown in Figure 3. The final plasmid structure was confirmed by additional restriction endonuclease digestions with BamHI, PvuII, BglI, EcoRI, and PstI and a double digestion with BglII and HpaI.

**pCLH3AXBPV-uPA Plasmid Construction**

The plasmid pCLH3AXBPV-uPA containing the human preprourokinase plasminogen activator gene in the sense direction was similarly prepared from pRdzbuktt and pCLH3AXBPV as described for pSV2-uPA. The plasmid pCLH3AXBPV, obtained from Dr. Gordon (Integrated Genetics, Framingham, MA) (Reddy et al., 1987), contains the bovine papilloma virus-1 (BPV-1) genome, mouse metallothionein (MT-1) promoter, a SV40 polyadenylation signal, the pML-1 (a derivative of pBR322 origin of replication), and an ampicillin resistant gene. The structure of the plasmid pCLH3AXBPV is shown in Figure 4. The pCLH3AXBPV was linerized by restriction endonuclease digestion with XhoI.
The plasmid pSV2-uPA contains the full length cDNA for human preprourokinase in the sense orientation, SV40 early and late gene promoters, a SV40 polyadenylation signal, the pBR322 origin of replication, and an ampicillin resistant gene. The SV40 early promoter directs the expression of the inserted human preprourokinase gene. The transcription is clockwise in the 5' to 3' direction. The outside plasmid circle, corresponding to the inner circle, shows several restriction enzymes used to verify the constructed pSV2-uPA structure.
Figure 4. Structure of the plasmid pCLH3AXBPV

The plasmid pCLH3AXBPV contains the bovine papilloma virus-1 (BPV-1) genome, the mouse metallotheionine (MT-1) promoter, a SV40 polyadenylation signal, a derivative of the pBR322 origin of replication (pML-1), and an ampicillin resistant gene. The plasmid was linerized by the restriction endonuclease digestion with XhoI to insert human preprourokinase gene. Several restriction enzymes used to verify the plasmid structure are shown on the map.
The pRdzbuktt was digested with HindIII and SacI and the human preprourokinase cDNA was separated by electrophoresis and eluted from the agarose gel. The pCLH3AXBPV vector and the human preprourokinase fragment were repaired to blunt ends with T4 DNA polymerase and a mixture of four deoxynucleotide triphosphates and the two ends were ligated. The construction scheme is shown in Figure 5. The ligated DNA was transformed in E-coli and the ampicillin resistant clones were selected. The selected clones were screened for pCLH3AXBPV-uPA by the restriction endonuclease digestions with HpaI, HindIII, and EcoRI. The final plasmid construction was confirmed by the additional restriction digestions with BamHI, PvuII, and a double digestion with PvuI and PstI. The plasmid structure and the restriction digestion map of the constructed pCLH3AXBPV-uPA is shown in Figure 6.

**pSV2-ASuPA Antisense Plasmid Construction**

The plasmid pSV2-ASuPA containing the 5’end 265-base-pair of preprourokinase sequence in the antisense direction was similarly prepared from pSV2-dhfr and pRdzbuktt as shown in Figure 7. The pSV2-dhfr was digested with HindIII and BglII and the vector fragment of pSV2 was separated by electrophoresis and eluted from the
Figure 5. Construction of human preprourokinase expression vector pCLH3AXBPV-uPA containing bovine papilloma virus-1 (BPV-1) and metallothionein-1 (MT-1) promoter

The human 1021 base pair preprourokinase cDNA gene (uPA) was obtained by digestion of plasmid pRdzbuukt with Sacl and HindIII. The plasmid pCLH3AXBPV was linerized by the digestion with XhoI. The uPA sequence was ligated to the linear pCLH3AXBPV to make the pCLH3AXBPV-uPA expression plasmid containing human preprourokinase gene in a sense direction with respect to the MT-1 promoter. Transcription is clockwise in the 5' to 3' direction. The hatched area represents the preprourokinase coding sequences.
Figure 6. Structure of the plasmid pCLH3AXBPV-uPA

The structure of plasmid pCLH3AXBPV-uPA is identical with that of pCLH3AXBPV except the full length cDNA for human preprourokinase was inserted in the sense orientation at XhoI site. The MT-1 promoter directs the expression of inserted human preprourokinase gene. The transcription is clockwise in the 5' to 3' direction. The outside plasmid circle, corresponding to the inner circle, shows several restriction enzymes used to verify the constructed pCLH3AXBPV-uPA structure.
Figure 7. Construction of human urokinase antisense gene expression vector pSV2-ASuPA.

The human 5’end 265 base pairs of preprourokinase cDNA was obtained by digestion of plasmid pRDziBuKTT with HindIII and NcoI. Plasmid pSV2-dhfr was digested with HindIII and BglII and the large fragment was purified. Two fragments were ligated at HindIII sites in an antisense direction. The cohesive ends of ligated DNA, NcoI and BglII sites, were blunted by T4 DNA polymerase followed by blunt ligation. Transcription is clockwise in the 5’ to 3’ direction.
agarose gel. The pRdzbuktt was digested with HindIII and NcoI and 265-base-pair fragment containing the human preprourokinase sequence was purified and eluted from the agarose gel. Two purified fragments were ligated at the HindIII site which resulted in a 265-base-pair fragment attached to pSV2-dhfr digest in an antisense orientation with respect to the SV40 early gene promoter. The cohesive ends of the ligated DNA were blunted with T4 DNA polymerase and a mixture of four deoxynucleoside triphosphates, ligated, and then transformed in HB101. The selected ampicillin resistant clones were analyzed for the correct orientation by restriction endonuclease digestions with BglI, PstI, and PvuII. The final pSV2-ASuPA plasmid construction was confirmed by additional restriction digestions with BglI and PstI and double digestions with PvuII-BamHI, BamHI-EcoRI, EcoRI-HpaI and HpaI-PvuI. The plasmid structure and the restriction endonuclease digestion map of the constructed pSV2-ASuPA structure is shown in Figure 8.

**DNA Transfection**

DNA transfection was performed by the calcium-phosphate coprecipitation technique of Graham and van der Eb (1973), with modifications. Twenty-four hours before
The plasmid pSV2-ASuPA contains the HindIII and NcoI digestion fragment of human preprourokinase in the antisense orientation with respect to the SV40 early gene promoter, the SV40 early and late gene promoters, a SV40 polyadenylation signal, the pBR322 origin of replication, and an ampicillin resistant gene. The SV40 early promoter directs the expression of the inserted human preprourokinase antisense gene. The transcription is clockwise in the 5' to 3' direction. The outside plasmid circle, corresponding to the inner circle, shows several restriction enzymes used to verify the constructed pSV2-ASuPA structure.
the transfection, approximately $5 \times 10^5$ cells were seeded in 100 mm Petri dishes containing Eagle’s MEM and 10% heat-inactivated FBS. The DNA used for transfection was purified by alkaline lysis extraction followed by CsCl density gradient centrifugation, and then dialyzed against TE-buffer (Maniatis et al., 1982). The DNA used for the transfection was in the form of closed circular plasmid DNA. Bl6-F1 cells were cotransfected with 10 ug of constructed plasmid containing the human preprourokinase gene (pSV2-uPA, pCLH3AXBPV-uPA or pRdzbuktt) and 1 ug of pSV2-neo (American Type Culture Collection). Bl6-F10 cells were cotransfected with 10 ug of pSV2-ASuPA and 1 ug of pSV2-neo. For the control, 1 ug of pSV2-neo alone was used. The CaPO$_4$/DNA mixture was prepared by combining DNA with 2 M CaCl$_2$ in HBSP buffer (1.5 mM Na$_2$HPO$_4$, 10 mM KCl, 280 mM NaCl, 12 mM glucose, 50 mM HEPES, pH 7.05) and was allowed to form a precipitate for 30 minutes at room temperature without any disturbance. All the solutions except DNA were kept sterile prior to transfection. The CaPO$_4$/DNA precipitate was then slowly added to the cells in a dropwise manner and the cells were incubated at 37°C in 5% CO$_2$ saturated with water vapor for 16 hours. At the end of the transfection period, the cells were shocked with 15% sterile glycerol in HBSP buffer for 3 minutes at
The cells were then allowed to recover in MEM supplemented with 10% heat inactivated FBS for 24 hours at 37°C. The cells were subcultured at a 1:3 ratio and transferred to MEM with 10% heat inactivated FBS containing 1.5 mg/ml Geneticin (G-418) (Gibco Laboratories, Grand Island, NY). The cells were provided with fresh MEM with 10% heat inactivated FBS containing Geneticin every three days. Two weeks after the initiation of Geneticin treatment, the transfected cells were monitored every day and about four weeks later the surviving cell colonies were further processed.

**Fibrin Overlay Assay for Plasminogen Activator**

The transient expression of the urokinase gene of the transfected cells were assayed by the fibrin overlay assay for plasminogen activator with minor modifications (Kenten *et al.*, 1986). Two days after the transfection, the cells were detached and collected from the petri dishes by incubation with 1 mM EDTA in PBS and then washed twice in serum-free MEM. The cell suspension solution (70% MEM supplemented with 10% heat inactivated FBS, 30% Hank's balanced salt buffer (Gibco Laboratories), supplemented with 2.5% low-gelling-temperature agarose) (type VII, A-4018, Sigma Chemical Co.) was prepared and
incubated at 42°C until the agarose was dissolved. To the 9 ml of cell suspension solution, 0.7 units of thrombin (from bovine plasma, T-6759, 276 units/ml, Sigma Chemical Co.) and $5 \times 10^4$ cells were added and rapidly mixed by inverting the test tube. Then 1.5 ml of MEM supplemented with 10% heat inactivated FBS containing 30 mg/ml fibrinogen (from bovine blood, F-4753, Sigma Chemical Co.) was rapidly added and the mixture was poured immediately into 100-mm petri dish. The dishes were incubated at 37°C in 5% CO$_2$ saturated with water vapor for 24 hr. After the incubation, the number of clearing zones which represent the presence of the cells that produce urokinase were counted. As a reference, C127 cells obtained from ATCC were transfected with pCLH3AXBPV-uPA and assayed in the same manner to detect urokinase activity in the transfected cells as documented by Reddy et al. (1987). For the positive control, 10 ul of human urokinase (High molecular weight urokinase, #124, 80,000 IU/mg, from American Diagnostica Inc., New York, NY) solution (3.6 ug/ml) was added dropwise on the agarose fibrin plate.

**Immunoblot Detection of Human Urokinase Production by Transfected Cell Colonies**

The surviving colonies of transfected cells were
analyzed for the production of human urokinase by a filter immunoblot assay (McCracken and Brown, 1984) with polyclonal antibody to high molecular weight human urokinase (American Diagnostica, New Haven, CN, Antibody #389). This assay was not used quantitatively, but only used to verify the presence of urokinase production in the colonies. Prior to the assay, the medium was removed from the petri dish containing transfected B16-F1 or B16-F10 colonies. The cells were washed twice with serum free medium (SFM), then 2.5 ml of SFM was added to the cell. An autoclaved disc of teflon mesh (Spectrum Medical Industries Inc., Los Angeles, CA) was placed over the cell colonies and a sterile notched nitrocellulose membrane filter disc (Millipore, Bedford, MA) was laid over the teflon mesh. The cell colonies were then incubated for 7 to 8 hours at 37°C. After the incubation, the filter and mesh were removed and the cells were re-fed with MEM containing 10% heat inactivated FBS with Geneticin until colony transfer. The filters were soaked in Denhardt’s solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% ovalbumin in 150 mM NaCl, 10 mM sodium phosphate, pH 7.4) for 16 hours at 4°C to block any non-specific binding sites, washed with PBS-Tween (PBS containing 0.05% Tween-20), and then incubated with 1:500 diluted rabbit
polyclonal antibody to human urokinase (American Diagnostica Inc., New York, NY, antibody #389) in PBS-Tween containing 0.1% ovalbumin for 2 hours at room temperature. The filters were subsequently washed and incubated with 1:300 diluted goat antirabbit IgG conjugated with alkaline phosphatase (Biorad, Richmond, CA) in PBS-Tween for 1 hour at room temperature. After the second antibody treatment, filters were again washed and incubated with BCIP/NBT (5-bromo-4-chloro-3-indoyl phosphate/nitroblue tetrazolium) solution (Biorad) in carbonate buffer (0.1 M NaHCO₃, 1.0 mM MgCl₂, pH 9.8) for alkaline phosphatase color development. After the filters were processed, photocopies and transparencies were made.

Quantification of Urokinase Production by ELISA

The transparencies made from the immunoblot filters were aligned with original culture dishes and twenty positive colonies, dark purple spots on the filters, were selected. These were transferred to separate petri dishes. The cells in each colony were picked up using yellow Pipetman tips after they were released from the Petri dishes by scraping under the microscope in a sterile hood. They were allowed to proliferate in MEM supplemented with 10% heat inactivated FBS. In order to
select the colonies that produce the highest amount of urokinase, the secretion of urokinase from each colony was quantitated by IMUCLONE Urokinase Plasminogen Activator ELISA Kit (American Diagnostica Inc., New York, NY). This ELISA Kit detects both single and two-chain urokinase (IMMUCLONE uPA ELISA Kit manual, American Diagnostica Inc.). Forty hours prior to ELISA, $2.5 \times 10^4$ cells were seeded in 25 mm petri dishes in serum free MEM and incubated at $37^\circ C$. A 100 ul aliquot of conditioned medium was removed from each colony and added to the ELISA plate wells coated with murine monoclonal antibody to human urokinase (high and low molecular weight urokinase). The plates were incubated for 90 minutes at $37^\circ C$ in the buffer provided by the manufacturer. The wells were then washed and incubated with rabbit anti-human urokinase conjugated with horseradish peroxidase at $37^\circ C$ for 1 hour. After incubation with the second antibody, the substrate was added for peroxidase color development and incubated for 30 minutes at room temperature. After the final incubation, the reaction was stopped with solution provided and absorbances were read at 405 nm in an ELISA microplate spectrometer (Minireader II, Dynatach Labs, Inc., Alexandria, VA). Each colony was tested in triplicate and three separate experiments were performed.
**southern Blot Hybridization Analysis of B16-F1 and B16-F1 pSV2-uPA transfected cells**

The genomic DNAs of B16-F1 cells, pSV2-neo transfected cells, and clone 7 (C7) of pSV2-uPA transfected B16-F1 cells were isolated by standard methods (Davis *et al.*, 1986). The genomic DNAs of B16-F1 and transfected B16-F1 cells and the pSV2-uPA plasmid were digested with BamHI or PstI and electrophoresed overnight on a 0.8% agarose gel. The DNAs were Southern blotted to nitrocellulose filter (Trans-Blot Transfer Medium, Bio-Rad) by the capillary transfer method. For the cDNA probe, pSV2-uPA was double digested with HpaI and PstI and the DNA fragment containing the preprourokinase sequence was purified by electrophoresis and DNA electroelution. The probe was labeled with $^{32}$P-dCTP by nick translation (Nick Translation System, BRL, Life Technologies, Inc., Gaithersburg, MD). Briefly, the probe DNA was added to the reaction mixture containing dATP, dGTP, dTTP, and $^{32}$P-dCTP (ICN Biomedicals, Inc., Irvine, CA) and nick translated by incubation with 1 U of DNA polymerase I and 100 pg of DNase I at 15°C for 60 minutes. The nick-translated CTP was separated from unincorporated $^{32}$P-labeled CTP by NICK-Column (Pharmacia Fine Chemicals, Uppsala, Sweden) which contains Sephadex G-50 DNA Grade.
The nitrocellulose filter was hybridized with $^{32}$P-labeled probe in hybridization solution containing 5X Denhardt's (1X Denhardt's = 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA), 1% SDS, 100 ng/ml denatured salmon sperm DNA, 1 M NaCl/10 mM Na$_3$PO$_4$ buffer, pH 6.5, at 65°C overnight. The filter was then washed four times for 30 minutes each wash with 0.2X SSC (1X SSC = 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) containing 0.5% SDS, at 65°C and exposed to X-ray film (Kodak X-OMAT AR Diagnostic Film, Eastman Kodak Co., Rochester, NY) at -70°C with an intensifying screen (Dupont Cronex Lighting Plus GJ 220004, Dupont Co., Wilmington, DE). To estimate the relative amounts of hybridization, the autoradiographs were scanned by a Gel Scan densitometer equipped with a Gilford Response UV-VIS Spectrometer (Gilford Systems, Oberline, OH).

**Southern Blot Hybridization Analysis of B16-F1 and B16-F1 pSV2-neo and pRdzbuett transfected cells to detect pSV2-neo incorporation**

The genomic DNAs of B16-F1 cells and pSV2-neo transfected cells, pSV2-neo and pRdzbuett cotransfected cells were similarly isolated. The prepared genomic DNAs and the plasmid pSV2-neo were digested with HindIII or double digested with HindIII and BamHI or HindIII and
electrophoresed overnight on a 0.8% agarose gel, and blotted to nitrocellulose filter. For the cDNA probe, pSV2-neo was digested with HindIII and PstI and the DNA fragment containing the neo gene was used. The probe was labeled with $^{32}$P-dCTP by nick translation. The nitrocellulose filter was similarly hybridized with the probe and exposed to X-ray film.

**Southern Blot Hybridization Analysis of B16-F1 and B16-F1 pRdzbuKtt transfected cells to detect pRdzbuKtt incorporation**

To detect the pRdzbuKtt incorporation, the plasmid pRdzbuKtt and the isolated cell DNAs were digested with HindIII or double digested with HindIII and SacI or HindIII and PstI and were separated by electrophoresis. DNAs were Southern blotted to nitrocellulose filter. For the cDNA probe, pRdzbuKtt was double digested with SacI and HindIII and the fragment containing the human preprourokinase gene was used for the hybridization. The probe was labeled with $^{32}$P-dCTP by nick translation. The nitrocellulose filter was similarly hybridized with the probe and exposed to X-ray film.
**southern Blot Hybridization Analysis of B16-F10 and B16-F10 Antisense Transfected Cells**

The genomic DNAs of B16-F10 cells, pSV2-neo transfected cells, and antisense clones 10 (AC10) and 8 (AC8) of pSV2-ASuPA transfected B16-F1 cells were similarly isolated, digested with PstI, and electrophoresed on a 0.8% agarose gel. The DNAs were Southern blotted to nitrocellulose filter. For the cDNA probe, pSV2-ASuPA double digested with HpaI and PstI and the DNA fragment containing the preprourokinase sequence was purified. The probe was labeled with $^{32}$P-dCTP by nick translation. The nitrocellulose filter was similarly hybridized with the probe and exposed to X-ray film.

**Northern Blot Hybridization Analysis of B16-F1 and B16-F1 Cells Transfected with pSV2-uPA**

The cytoplasmic RNAs of B16-F1, B16-F1 pSV2-neo transfected cells, and pSV2-uPA transfected cells (clone 7 and 10) were extracted by a standard method (Ausubel et al., 1988). Briefly, the cells were washed and collected in cold PBS and lysed in ice-cold lysis buffer (50 mM Tris-Cl, pH 8.0, 100 mM NaCl, 5 mM MgCl$_2$, 0.5% Nonidet P-40 in DEPC-treated water). The contaminating proteins
were denatured with proteinase K and the RNA was purified by phenol extraction. The prepared RNAs were separated overnight by electrophoresis in 1% agarose/0.02% formaldehyde gel in MOPS buffer (0.2 M MOPS, 0.05 M sodium acetate, 0.01 M EDTA). The RNAs were transferred to Nytran Nylon Membrane (Schleicher & Schuell, Keene, NH) by the capillary transfer method, and immobilized by a covalent bond using the UV crosslinking technique (UV Stratalinker 1800, Stratagene, La Jolla, CA). For the cDNA probe, pSV2-uPA was double digested with BamHI and PstI and the DNA fragment containing preprourokinase sequence was labeled with $^{32}$P-dCTP by nick translation. The Nytran filter was hybridized with $^{32}$P-labeled probe in hybridization solution containing 50% formamide, 2.5X Denhardt's reagent, 200 ug/ml of denatured salmon sperm DNA, 0.5% SDS, and 5X SSPE (1X SSPE = 0.18 M NaCl/10 mM NaPO$_4$, pH 7.7/1 mM EDTA) at 42°C overnight. The filter was washed twice in 6X SSPE and 0.5% SDS at room temperature, twice in 1X SSPE and 0.5% SDS at 37°C, and once in 1X SSPE and 0.5% SDS at 60°C. The filter was exposed to X-ray film at -70°C. To rehybridize the blot, the pSV2-uPA probe was removed by boiling the filter for 20 minutes in 0.01X SSPE/0.5% SDS and rinsing twice in 2X SSPE. For the internal standard control, the stripped
filter was similarly hybridized with $^{32}$P-labeled *Drosophila* actin (Fryberg et al., 1983) obtained from Dr. Mark Kelley (Loyola University Medical Center) and exposed to X-ray film.

**Assay of the Binding of Human Urokinase to the Human PC3-Met Cell Line and the Murine B16-F1 Cell line**

The binding of human urokinase to B16-F1 or PC3-Met cells (obtained from Dr. James Kozlowski, Northwestern University, Chicago, IL) was determined by the procedure of Stoppelli et al. (1985), with modifications. For B16-F1 cells, $5 \times 10^5$ cells were seeded in 2 ml of MEM supplemented with 10% heat-inactivated FBS in 6-well plate (Elkay Products, Inc., Shrewbury, MA) and incubated at 37°C in 5% CO$_2$ for 24 hours prior to the assay. For PC3-Met cells (Kozlowski et al., 1984), $2.5 \times 10^5$ cells were similarly seeded in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS. The cells were gently washed twice with PBS containing 1 mg/ml of bovine serum albumin (BSA). In order to unmask urokinase receptors on the cell surface, the cells were incubated for 3 minutes at room temperature in 50 mM glycine-HCl buffer, pH 3.0, containing 0.1 M NaCl, and quickly neutralized with 0.5 M HEPES buffer, pH 7.5,
containing 0.1 M NaCl (Stoppelli et al., 1986). The acid treated cells appeared undamaged and bound to the plates. The cells were then washed twice with serum-free MEM containing 20 mM HEPES, pH 7.5, and 1 mg/ml of BSA and incubated for 1 hour at 37°C in the same buffer containing 4x10^4 cpm of 125I labeled human urokinase (see below) to which different concentrations of unlabeled human urokinase (American Diagnostica Inc., high molecular weight, #124, 80,000 IU/mg) were added. After incubation, the cells were washed four times with PBS containing 1 mg/ml of BSA and lysed by incubation in 20 mM HEPES buffer, pH 7.5, with 1% Triton X-100 and 10% glycerol for 30 minutes at room temperature. The lysed cells were counted in a gamma-ray counter (1191 Gamma Trac, Tm Analytic, Inc., Elk Grove Village, IL). Nonspecific binding was determined in the presence of excess (50 nM) unlabeled human urokinase and subtracted from the each experimental value. Each experimental concentration was performed in triplicate and the results were plotted as the mean cpm ± standard deviation.

125I Labeling of Human Urokinase

Three Iodo-Beads (Pierce Chemical Co., Rockford, IL) and 1 mCi of Na^{125}I in NaOH (IMS300, Amersham Corp.,
Arlington Heights, IL) were incubated in 0.05 M KHPO₄, 0.2 M NaCl, pH 7.5, at room temperature for 5 minutes with gentle shaking. Human urokinase (High molecular weight urokinase, #124, 80,000 IU/mg from American Diagnostica Inc., New York, NY), 50 ug, was added to the iodination mixture and incubated at room temperature for 20 minutes with gentle shaking. The ¹²⁵I human urokinase was separated from free Na¹²⁵I by gel filtration through a 9 ml Bio-Gel P-6 column (100-200 Mesh, Bio-Rad Laboratories) which was presaturated by washing with five column volumes of the above buffer containing 2 mg/ml of BSA. The urokinase ¹²⁵I fractions were combined and dialyzed extensively against 0.05 M KHPO₄, 0.2 M NaCl buffer with 1 mM KI overnight and then against 0.05 M KHPO₄, 0.2 M NaCl buffer. The amount of protein was determined by the BIO-RAD Protein Assay Kit (Bio-Rad Laboratories) according to the manufacturer’s instruction.

**Determination of Glycosylation of Human Urokinase**

A Concanavalin A affinity chromatography column was used to determine if human urokinase produced by transfected murine cells was glycosylated. Con A-Sepharose (Pharmacia Fine Chemicals, Upppsala, Sweden) (1 ml) was packed in a blue Eppendorf pipette tip and washed
with 50 mM Tris buffer, pH 7.5. The resin was further prepared by washing with buffer containing 100 mM sodium acetate, 1 mM NaCl, 10 mM CaCl$_2$, 10 mM MgCl$_2$, pH 6.0. Conditioned medium, prepared by incubating 5x10$^5$ cells of clone 7 of pSV2-uPA transfected B16-F1 in 2 ml of serum free MEM in a 6-well plate for 40 hours at 37°C, was collected and applied to the ConA sepharose column. The column was washed with four column volumes of 50 mM Tris buffer and then with the same buffer containing 0.5 M alpha-methyl-D-mannoside (Sigma Chemical Co.) to elute the glycosylated protein from the resin. Fractions of 400 ul were collected and assayed for human urokinase by the IMUCLONE Urokinase Plasminogen Activator ELISA Kit (American Diagnostica, Inc.) using a monoclonal antibody to human urokinase, as described above.

**Collection of Conditioned Medium for Quantification of Urokinase Activity Secreted by Cultured Cells**

The cells were plated in 6-well cell culture plates at a concentration of 2 x 10$^5$ cells per well in MEM supplemented with 10% heat-inactivated FBS and incubated overnight at 37°C in a 5% CO$_2$ atmosphere. The cells were rinsed twice with serum free medium (SFM) and incubated for 24 hours in SFM at 37°C in a 5% CO$_2$ atmosphere. The
cell conditioned media was collected and the cells were harvested and counted.

**Fluorogenic Substrate Assay for Plasminogen Activator Activity**

Plasminogen activator activity was measured by fluorescence spectroscopy as described by O'Donnell-Tormey and Quigley (1983). Cells to be assayed were collected by incubation with 0.25% of trypsin (Worthington Biochemical Corp., Freehold, NJ) in PBS containing 1 mM EDTA for few seconds. Cells were washed with PBS three times and resuspended in HEPES buffer (5% dimethyl sulfoxide in 0.05 M HEPES, pH 7.4) at the concentration of 1 x 10^6 cells/ml. Cell suspension solution (400 ul) was mixed with 170 ul of HEPES buffer, 30 ul of fluorogenic substrate for plasminogen activator, methoxysuccinyl-L-Gly-L-Gly-L-Arg-7-amino-4-methylcoumarin HCl (Bachem Fine Chemicals, Inc., Torrance, Calif.) (final concentration of 10 mM). The release of 7-amino-4-methylcoumarin (AMC) from the substrate was measured in a Perkin-Elmer MPF-44B Fluorescence Spectrophotometer at an excitation wave length of 380 nm and an emission wave length of 460 nm. The linear release of AMC was recorded for 5 minutes and the slope of the linear curve was measured. To calibrate
the instrument, 7-amino-4-methyl coumarine (Sigma Chemical Co.) was used as a standard. For the standard curve, different dilutions of human urokinase (High molecular weight urokinase, #124, from American Diagnostica Inc., New York, NY) were used instead of cells.

**Chromogenic Substrate Assay for Plasminogen Activator Activity**

Plasminogen activator activity was measured spectroscopically using a chromogenic substrate for plasmin as previously described by Whur et al. (1980). Ten μl of cell conditioned media was added to 100 μl of 100 mM Tris buffer, pH 8.1, containing 5 μg of plasminogen (Sigma Chemical Co.), 15 μg of S-2251 (H-D-Val-Leu-Lys-p-nitroanilide, KabiVitrum, Stockholm, Sweden), and 0.1% Triton X-100 in 96-well plates. Plasminogen was treated, prior to use, to inhibit any active plasmin activity by incubating plasminogen with diisopropylfluorophosphate (DFP) at 25 mM in 50 mM Tris buffer, pH 8.1, at 37°C for 1 hour and then extensively dialyzing against the same buffer. Plasmin activity was measured with DFP-treated plasminogen to ensure plasmin activity was no longer detected by the same assay. The plates were incubated for 16 hours at 37°C in a 5% CO₂ atmosphere. After incubation,
the p-nitroaniline absorbances, corresponding to substrate hydrolysis by plasmin, were read at 405 nm in a spectrometer (Minireader II, Dynatech Labs, Inc., Alexandria, VA).

To test the stability of urokinase gene expression in the transfected cells in a longer period of time, one of the flask of Clone 7 of pSV2-uPA transfected B16-F1 cells were passaged more than 20 times. The conditioned medium was collected from that particular flask and assayed for the plasminogen activator activity by the same method. Determination of the standard curve of plasminogen activator activity and nonspecific activity were included in each assay.

The nonspecific activity was determined in the absence of cell conditioned medium and subtracted from each experimental value. For the background activity, reaction buffer was used instead of plasminogen for the assay. Each experiment was performed in triplicate and five separate experiments were assayed. Plasminogen activator activity was expressed in pg secreted in the conditioned medium per cell per hour.

125I-fibrin Plate Assay for Plasminogen Activator Activity

The procedure was similar to that described
previously by Strickland and Beers (1976). Bovine fibrinogen (Sigma Chemical Co.) was iodinated with \( \text{Na}^{125}\text{I} \) by the same procedure as described above for the \( \text{I}^{125} \) labeling of human urokinase. The specific radioactivity of the fibrinogen was adjusted to 15,000 cpm/ug of fibrinogen by the addition of unlabeled fibrinogen. To each well of a 24-well plate (Gibco Laboratories), 250 ul of \( \text{I}^{125} \)-fibrinogen in 50 mM Tris buffer, pH 8.1 (50,000 cpm per well) was added and dried in a 37° C dry oven for two days. Prior to use, wells were incubated with 500 ul of MEM supplemented with 5% plasminogen-depleted FBS at 37° C in a 5% CO\(_2\) atmosphere to convert fibrinogen to fibrin. Plasminogen-depleted FBS was prepared by repeated incubation of FBS at 56° C for 45 minutes. Wells were washed three times with 50 mM Tris buffer, pH 8.1 and incubated for 2 hours with 100 ul of cell conditioned medium, 75 ug of BSA and 10 ug of DFP treated plasminogen (Sigma Chemical Co.) in the 300 ul of same buffer at 37° C in a 5% CO\(_2\) atmosphere. At the end of the incubation period, a 100 ul aliquot of supernatant was taken from each well and counted in a gamma-counter. Nonspecific activity was determined in the absence of conditioned medium and subtracted from each experimental value. For the background activity, reaction buffer was used instead
of plasminogen for the assay. A standard curve was included in every assay. Each experiment was performed in triplicate and five separate experiments were assayed. Plasminogen activator activity was expressed in pg secreted in the conditioned medium per cell per hour.

**Murine Lung Colonization Assay**

The murine B16-F1 or B16-F10 melanoma lung assay was performed in a similar manner as previously described by Fidler (1978). Transfected B16-F1 or B16-F10 cells were grown to semi-confluency (80-90%) in MEM supplemented with 10% heat inactivated FBS and harvested by the addition of 1 ml of 1 mM EDTA in PBS, pH 7.4 at 37°C for 1 minute. MEM supplemented with 10% heat inactivated FBS was added, centrifuged, and resuspended in PBS. The cells were counted using a Coulter Counter (Coulter Electronics, Inc., Hialeah, FL) and diluted to 5x10^5 cells/ml. The viability of the cells was determined by counting trypan blue exclusion. The cells were maintained on ice prior to injection. A total of 26 female C57BL/6 mice, 6-8 weeks old (Harlan Laboratories, Indianapolis, IN) were equally divided into control and experimental groups. Mice were housed in the Loyola Medical Center Animal Research Facility for one week prior to use. A 0.2 ml aliquot of
cell suspension (100,000 cells per mouse) were slowly injected into the lateral tail vein of each mouse while immobilized in a mouse vice. The injection schedule alternated between mice in the control group and mice in the experimental group to minimize the variance in time. The animals were sacrificed 17 days after the injection of transfected cells by administering an overdose of ether. The lungs were removed and fixed in Bouin's solution (0.75% picric acid, 25% formaldehyde, 5% glacial acetic acid) overnight. The number of surface tumor colonies, easily visible as black or white nodules on the yellow Bouin's background, were counted under a dissecting microscope.

**Spontaneous Metastasis Assay**

The assay of spontaneous metastasis from a foot pad tumor was carried out by the procedure of Fidler (1986), with minor modifications. Cells were grown to semi-confluency in MEM supplemented with 10% heat inactivated FBS, harvested, and tested for viability, and counted as described above. Female C57BL/6 mice, 6-8 weeks old (Harlan Laboratories) were housed in the Loyola Medical Center Animal Care Facility for one week prior to use. Mice were lightly anesthetized with ether and injected
subcutaneously into a posterior footpad with $10^5$ cells of clone 7 of B16-F1 transfected cells for experimental animals or pSV2-neo transfected cells for a control. The cells for injection were suspended in 0.05 ml of PBS. An 1/2 inch 27-gauge needle was inserted into the dorsal aspect of the foot for injection. Three weeks later, after allowing the cells to grow into the primary site, mice were lightly anesthetized with the inhalation anesthetic, Metofane (Methoxyfurane) (Pitman-Moore, Inc., Washington Crossing, NJ) and the tumor-bearing foot was amputated with a pair of scissors. The wound was cauterized and drawn together with wound clips (Becton Dickinson & Co., Parsippany, NJ). Mice were injected with 15 ug of Buprenex (Buprenorphine HCl, Reckitt & Colman Pharmaceutical, Inc., Norwich, NY) to relieve the pain and returned to their cages. After an additional 3-4 weeks, the animals were sacrificed by an overdose of ether. The lungs were removed and fixed in Bouin’s solution overnight. The number of surface tumor colonies were counted under a dissecting microscope.

**Culture of Lung Colony Tumor Cells**

C57BL/6 mice were injected with 100,000 cells of Clone 7 of pSV2-uPA transfected B16-F1 cells or pSV2-neo
transfected B16-F1 cells. Animals were sacrificed 17 days after injection. The lungs were removed aseptically, cut into small pieces with sterile razor blades, and plated in vitro on petri dishes containing MEM supplemented with 10% heat-inactivated FBS. The medium was changed after the cultures adhered to the petri dishes. The cells were maintained in the same manner as B16-F1 cells when the cultures became confluent.

**Cytotoxicity Assay**

The cytotoxicity assay was performed to test the immunologic responses in C57BL/6 mice against transfected murine cells which produce human urokinase. The procedure is similar to that described by Hirschberg et al. (1977). Spleens were collected at the time of sacrifice from the mice which were injected with transfected cells. Lymphocytes were harvested from the spleens and served as cytotoxic effectors. The targets cells, B16-F1 transfected with pSV2-neo or clone 7 of pSV2-uPA transfected cells, were labeled with $^{51}$Cr. Cytotoxic effectors were mixed with target cells at the ratio of 50:1, 25:1, 12:1 or 6:1 and incubated for 4 hours at 37°C. The mixture was centrifuged and the supernatant was harvested and counted for radioactivity in a gamma counter.
and % specific release was calculated. The spleen from the uninjected animal and B16-F1 untransfected cells were used as a control.

**Statistical Analysis of Data**

Numerical data was expressed as the mean ± standard deviation or the mean ± standard error of several determinations. To compare the data between the control and experimental groups, Student t test and Mann Whitney U-Test (nonparametric rank sum test) were used. P values of < 0.05 were considered to represent significant difference between two groups.
Chapter IV

RESULTS

I. The Production of Human Urokinase in Murine B16-F1 Melanoma Cells and The Study of Its Effect on Tumor Cell Metastasis

Expression of Human Preprourokinase Gene

To express the human preprourokinase gene in B16-F1 melanoma cells, the plasmid pSV2-uPA which contains human preprourokinase cDNA in a sense direction with respect to the SV40 early gene promoter, was prepared. For the synthesis of pSV2-uPA, the dihydrofolate reductase gene of the plasmid pSV2-dhfr was replaced by the preprourokinase gene isolated from the plasmid pRdzbuktt. The detailed steps involved in subcloning preprourokinase cDNA into pSV2 vector are summarized in Figure 2. The correct plasmid which contained the preprourokinase gene in the sense direction was selected by restriction endonuclease digestion profile which is shown in Figure 3.
To introduce the human prourokinase gene into B16-F1 melanoma cells, transfection technique was used. Transfection was carried out by using calcium phosphate precipitation with DNA followed by a glycerol shock. Cells were cotransfected with plasmids pSV2-uPA and a selection marker gene pSV2-neo in 10:1 ratio, or transfected with the pSV2-neo alone for the control. In the pSV2-neo, SV40 early gene promotes the expression of an aminoglycoside phosphotransferase from the E. coli transposable element Tn5. Expression of aminoglycoside phosphotransferase confers upon mammalian cells resistance to the toxic aminoglycoside G-418 (Geneticin), a neomycin analog. Therefore the pSV2-neo recipient mammalian cells gain the capability to survive in Geneticin upon successful transfection. To select transfected colonies, cells were grown in the presence of Geneticin (G-418) for four to five weeks. The transfection efficiency in the B16-F1 cell line by the transfection condition described on Materials and Methods section is shown to be about one transformant in 5,000 transfected cells when the closed circular plasmid DNA was used for transfection. The linerized plasmid DNA gave significantly low transfection efficiency (data not shown). The efficiency of transfection was not increased by using a carrier DNA such
as 10 ug/ml of salmon sperm DNA for transfection (data not shown). A change of fresh MEM prior to transfection did not affect transfection efficiency (data not shown). Cells appeared to be damaged and were lifted off from the petri dish if they were shocked longer than 5 minutes. The best transfection results were obtained when the cells underwent at least two cell divisions if thawed from the frozen stock and appeared very healthy before the transfection.

The surviving colonies expressing the neo gene were assayed for the coexpression of the human preprourokinase gene by a filter immunoblot assay as shown in Figure 9. In this assay, all the proteins being secreted from the colonies expressing preprourokinase gene were absorbed to nitrocellulose filter. The filter was treated with polyclonal antibody to human urokinase to select for the positive colonies that produce human urokinase. Figure 9 shows that pSV2-uPA and pSV2-neo transfected cells generated many positive colonies detected by the dark color development. However pSV2-neo transfected control cells show the absence of color development which indicates these cells do not produce human urokinase.

Twenty positive colonies detected for human urokinase secretion by filter immunoblot assay were
Figure 9. Filter immunoblot analysis of transfected B16-F1 cell colonies

B16-F1 cells were transfected with pSV2-neo (top) or cotransfected with pSV2-uPA and pSV2-neo (bottom). Transfected cells were cultured in MEM supplemented with 10% heat inactivated FBS containing Geneticin (G-418). Five weeks later, nitrocellulose membrane filters were placed over the cell colonies to absorb urokinase being secreted. The filters were treated with rabbit polyclonal antibody to human urokinase followed by goat anti-rabbit IgG conjugated with alkaline phosphatase, which were reacted with NBT/BCIP to give dark purple color development. The spots on the filters correspond to the transfected foci expressing human urokinase.
selected, transferred to separate petri dishes, and expanded in MEM supplemented with 10% heat inactivated FBS. Secretion of human urokinase into the cell culture medium from each colony was then quantitated by a sandwich type ELISA using a monoclonal antibody against high molecular weight human urokinase as the primary antibody and polyclonal antibody against high and low molecular weight human urokinase as the detecting antibody. Monoclonal antibody to human urokinase has been reported to identify the single-chain prourokinase as well as two-chain urokinase (Sallerno et al., 1984). The ELISA Kit (American Diagnostica Inc.) was used for the assay to detect both single and two-chain urokinase. Table 1 shows that clone 7, 8, 10, and 18 secreted the highest amount of human urokinase out of 20 positive selected clones. B16-F1 or B16-F10 untransfected cells give absorption value equal to zero, as no human urokinase is produced.

The incorporation of human preprourokinase gene to genomic DNA of transfected cells was demonstrated by a Southern blot hybridization assay as shown in Figure 10. The DNAs were prepared from clone 7 of pSV2-uPA transfected cells and B16-F1 untransfected cells, digested with BamHI or PstI, separated by electrophoresis, blotted, and probed with $^{32}$P labeled human preprourokinase cDNA.
Table 1. Quantification of human urokinase production by B16-F1 transfected cells with pSV2-uPA detected by ELISA\textsuperscript{a}

<table>
<thead>
<tr>
<th>Clone No</th>
<th>Absorbance (Mean±SD)</th>
<th>Clone No</th>
<th>Absorbance (Mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>1.79 ± 0.06</td>
<td>C11</td>
<td>2.71 ± 0.15</td>
</tr>
<tr>
<td>C2</td>
<td>0.25 ± 0.03</td>
<td>C12</td>
<td>0.14 ± 0.15</td>
</tr>
<tr>
<td>C3</td>
<td>1.17 ± 0.01</td>
<td>C13</td>
<td>2.81 ± 0.06</td>
</tr>
<tr>
<td>C4</td>
<td>0.72 ± 0.04</td>
<td>C14</td>
<td>0.13 ± 0.02</td>
</tr>
<tr>
<td>C5</td>
<td>0.87 ± 0.04</td>
<td>C15</td>
<td>0.34 ± 0.05</td>
</tr>
<tr>
<td>C6</td>
<td>0.09 ± 0.03</td>
<td>C16</td>
<td>0.72 ± 0.07</td>
</tr>
<tr>
<td>C7</td>
<td>4.24 ± 0.28</td>
<td>C17</td>
<td>0.51 ± 0.02</td>
</tr>
<tr>
<td>C8</td>
<td>2.97 ± 0.12</td>
<td>C18</td>
<td>3.22 ± 0.24</td>
</tr>
<tr>
<td>C9</td>
<td>0.10 ± 0.03</td>
<td>C19</td>
<td>1.57 ± 0.08</td>
</tr>
<tr>
<td>C10</td>
<td>3.43 ± 0.13</td>
<td>C20</td>
<td>1.63 ± 0.05</td>
</tr>
<tr>
<td>B16F1</td>
<td>0.08 ± 0.03\textsuperscript{b}</td>
<td>B16F10</td>
<td>0.08 ± 0.04\textsuperscript{b}</td>
</tr>
</tbody>
</table>

\textsuperscript{a}The secretion of urokinase from each colony was quantitated by IMUCLONE uPA ELISA Kit (American Diagnostica Inc.) on conditioned media taken from the cells incubated in the serum free media for 40 hours.

\textsuperscript{b}Value equal to zero as no human urokinase is produced by murine B16-F1 cells which were not transfected with the pSV2-uPA plasmid.
Figure 10. Southern blot hybridization analysis of DNA isolated from clone 7 of pSV2-uPA transfected B16-F1 and B16-F1 untransfected cells

DNAs were isolated from clone 7 of transfected B16-F1 cells and untransfected B16-F1 cells. The DNAs (10 ug) were cleaved with PstI or BamHI and electrophoresed through 0.8% agarose gel. A control pSV2-uPA plasmid preparation was similarly digested with PstI or BamHI and different amounts were loaded on the same gel. The DNAs were transferred to nitrocellulose and probed with $^{32}$P-labeled HpaI-PstI fragment of pSV2-uPA. Lanes 1-2 contain DNA made from $7 \times 10^6$ cells of clone 7 of pSV2-uPA transfected cells and lanes 3-4 contain DNA made from $7 \times 10^6$ untransfected cells. Lanes 5-6 contain DNA made from $3.5 \times 10^6$ cells of clone 7 and lanes 7-8 from $3.5 \times 10^6$ untransfected cells. Lanes 9-10, lanes 11-12, lanes 13-14 contain pSV2-uPA DNA of 10, 5, 2 ng respectively. Lanes 1,3,5,7,9,11,13 contain DNA digested with BamHI and lanes 2,4,6,8,10,12,14 contain DNA digested with PstI.
The digestion of pSV2-uPA with BamHI generates two DNA bands with base pairs of 4647 and 896 and the $^{32}\text{P}$-labeled probe hybridizes with both bands. The digestion of pSV2-uPA with PstI generates three DNA bands with base pairs of 2327, 2258, and 958 and the $^{32}\text{P}$-labeled probe hybridizes with 2327 and 2258 bands. As shown in Figure 10, clone 7 DNA digested with BamHI (lanes 1 and 5) showed two DNA bands of 4647 and 896 base pairs same as BamHI digested pSV2-uPA (lanes 9, 11, and 13). Again clone 7 DNA digested with PstI (lanes 2 and 6) showed one combined band of 2327 and 2258 base pairs same as PstI digested pSV2-uPA (lanes 10, 12, and 14). Therefore clone 7 demonstrates the restriction endonuclease digested bands identical to those of pSV2-uPA while the untransfected cells (lanes 3, 4, 7, and 8) show the absence of these bands.

The DNA copy numbers of human preprourokinase cDNA in clone 7 were estimated from a densitometer scan of autoradiographs by comparing the amounts of hybridization of a $^{32}\text{P}$-labeled probe to the genomic DNA of clone 7 cells (lanes 2 and 6) with known amounts of pSV2-uPA plasmids (lanes 10, 12, and 14). Figure 11 demonstrates the densitometer scan of lanes 2 (peak A), 6 (peak B+C), 10 (peak D), 12 (peak E), and 14 (peak F) of Figure 10.
Figure 11. Densitometer scan of autoradiographs of $^{32}$P hybridized to the genomic DNA of clone 7 or pSV2-uPA plasmid DNA

The DNA copy numbers of human preprourokinase cDNA in clone 7 were estimated from a densitometer scan of autoradiographs by comparing the amounts of hybridization of a $^{32}$-labeled probe to the genomic DNA of clone 7 cells with known amounts of pSV2-uPA plasmids. Peak A (lane 2 of Figure 10) with peak area of 12.9 represents DNA prepared from $7 \times 10^6$ cells, peak B+C (lane 6 of Figure 10) with peak area of 7.12 represents DNA made from $3.5 \times 10^6$ cells. Peaks D (lane 10 of Figure 10), E (lane 12 of Figure 10), and F (lane 14 of figure 10) which show peak area of 15.0, 8.93, and 2.40 represent 10, 5, and 2 ng of pSV2-uPA DNA respectively.
ANALYSIS =
SAMPLE = 1

<table>
<thead>
<tr>
<th>PEAK</th>
<th>LOCATION</th>
<th>PEAK MAX</th>
<th>PEAK AREA</th>
<th>%TOTAL AREA</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>16.76</td>
<td>2.0820</td>
<td>12.9362</td>
<td>27.90</td>
</tr>
<tr>
<td>B</td>
<td>52.45</td>
<td>0.9820</td>
<td>3.8075</td>
<td>8.21</td>
</tr>
<tr>
<td>C</td>
<td>56.64</td>
<td>0.9151</td>
<td>3.3140</td>
<td>7.15</td>
</tr>
<tr>
<td>D</td>
<td>92.33</td>
<td>2.0734</td>
<td>14.9871</td>
<td>32.32</td>
</tr>
<tr>
<td>E</td>
<td>108.84</td>
<td>1.1742</td>
<td>8.9285</td>
<td>19.26</td>
</tr>
<tr>
<td>F</td>
<td>130.56</td>
<td>0.2684</td>
<td>2.3954</td>
<td>5.17</td>
</tr>
</tbody>
</table>
showing peak areas of 12.9, 7.12, 15.0, 8.93, and 2.40 respectively. Peak A and peak B+C represent DNAs prepared from $7 \times 10^6$ cells and $3.5 \times 10^6$ cells of clone 7. Peaks D, E, and F represent 10 ng, 5 ng, and 2 ng of pSV2-uPA respectively, and accordingly approximately $1 \times 10^9$, $5 \times 10^8$, $2 \times 10^8$ copies of pSV2-uPA. By the comparison of peak areas of A and B+C with D, E, and F, the copy numbers of pSV2-uPA in clone 7 lanes were estimated. The estimated copy numbers were divided by the clone 7 cell numbers from which the DNA was prepared to calculate the copy numbers present per cell of clone 7. The calculations by the comparison of A with D, E, or F gave copy numbers of 131, 123, or 168 respectively and by the comparison of B+C with D, E, or F gave copy numbers of 149, 156, or 185. On average, therefore, approximately 150 copies of pSV2-uPA were shown to be incorporated within the genomic DNA of clone 7.

The expression of human preprourokinase mRNA was determined by Northern blot hybridization assay as shown in Figure 12. The cytoplasmic RNAs from clones 7 and 10 of pSV2-uPA transfected cells, pSV2-neo transfected cells, and untransfected B16-F1 cells were extracted, separated by formaldehyde/agarose gel, transferred to filter, and probed with $^{32}$P-labeled human preprourokinase cDNA. The
Figure 12. Northern blot hybridization analysis of RNA isolated from clone 7 and clone 10 of pSV2-uPA transfected cells, pSV2-neo transfected cell, and B16-F1 untransfected cells

The cytoplasmic RNAs of B16-F1, B16-F1 transfected cells were extracted, separated by The filter was hybridized with $^{32}$P-labeled human preprourokinase cDNA probe and exposed to X-ray film. The 2.3 Kb band on the clone 7 and clone 10 lanes demonstrates human urokinase mRNA expression, while this band is absent in B16-F1 or B16-F1 pSV2-neo transfected cell RNA. For the internal standard, $^{32}$P-labeled Drosophila actin was used.
The expression of clone and clone 10 indicates the presence of Actin.

The ELISA data (Table 1) showed C7 and secreted human urokinase activity with absorbance...
lanes with clone 7 and 10 RNAs show distinct bands which represent a 2.3 Kb mRNA of human preprourokinase gene while the lanes with B16-F1 untransfected cells and pSV2-neo transfected cells show absent of that band. The internal standard of $^{32}$P-labeled Drosophila actin shows that similar amounts of RNA were applied to each lane of the gel.

Figure 13 shows a densitometer scan of autoradiographs of a $^{32}$P-labeled probe to the RNA of clone 7, 10 or pSV2-neo transfected cells. The densitometer scan of human urokinase RNA of clone 7 (lane 3 of Figure 12, peak A) and clone 10 (lane 4 of Figure 12, peak B) gave the peak area of 1.71 and 1.88 respectively. The densitometer scan of Drosophila actin RNA of lane 3 of Figure 12 (peak D+E) and lane 4 of Figure 12 (peak F+G) gave the peak area of 0.97 and 1.27 respectively. The relative amount of human preprourokinase mRNA expression in clone 7 and 10 was estimated by calculating the ratio of peak areas of human urokinase to actin. The ratio of peak A/peak D+E (1.71/0.97) and peak b/peaks F+G (1.88/1.27) gave the value of 1.76 and 1.48 which indicate human preprourokinase mRNA expression of clone 7 and clone 10 respectively. The ELISA data (Table 1) showed C7 and C10 secreted human urokinase activity with absorbance
The relative amount of RNA of human preprourokinase in clone 7 and clone 10 were estimated from a densitometer scan of autoradiographs by comparing the amounts of hybridization of a $^{32}$P-labeled probe to the internal standard of *Drosophila* actin RNA. In the top figure, peak A (lane 3 of Figure 12) with peak area of 1.71 represents human urokinase RNA prepared from clone 7 cells, peak B (lane 4 of Figure 12) with peak area of 1.88 represents human urokinase RNA made from clone 10 cells. In the bottom figure, peaks D+E (lane 3 of Figure 12), F+G (lane 4 of Figure 12) which show peak area of 0.97 and 1.27 represent *Drosophila* actin.
ANALYSIS =
SAMPLE = 1
value of 4.24 and 3.43 respectively. The ratio of human urokinase versus mRNA was calculated to be 2.41 (4.24/1.76) for C7 and 2.32 (3.43/1.48) for C10. The ratio of mRNA expression and human urokinase secretion between C7 and C10 is shown to be similar: 1.19 (1.76/1.48) for mRNA and 1.24 (4.24/3.43) for urokinase.

Characterization of Human Urokinase produced by Murine Cells

Human urokinase is a glycoprotein (Holmes et al., 1985) whereas the murine urokinase lacks glycosylation sequences and is not glycosylated (Belin et al., 1985). Since the human urokinase is synthesized by transfected murine cells, the possible glycosylation of the human urokinase was tested by Concanavalin A column chromatography, which tightly binds polysaccharides and glycoproteins containing alpha-D-mannopyranosyl, alpha-D-glucopyranosyl and sterically related residues (Narasimha et al., 1979). Tightly bound glycoproteins can be eluted by the addition of alpha-methyl-D-mannoside to the buffer (Aspberg and Porath, 1970). The added alpha-methyl-D-mannoside will compete for the carbohydrate binding sites on the ConA, and cause the dissociation of any bound
glycoproteins. The column eluents before and after the addition of alpha-methyl-D-mannoside to the elution buffer were collected and assayed for the human urokinase by ELISA with specific monoclonal antibody to human urokinase. The results in Figure 14 show that human urinary urokinase (purchased from American Diagnostica, Inc.) contained a non-binding form of urokinase that was eluted prior to the alpha-methyl-D-mannoside wash, and a second peak eluted with alpha-methyl-D-mannoside buffer which corresponds to a glycosylated urokinase. The first unglycosylated urokinase peak might be generated from the urokinase from which carbohydrate moiety was degraded during the protein purification procedures or storage. The pSV2-uPA transfected murine B16-F1 clones produced only one human urokinase peak which was eluted with alpha-methyl-D-mannoside and coincided with the glycosylated urokinase peak observed in the human urokinase preparation. This result demonstrates that human urokinase produced by the transfected murine B16-F1 cells is glycosylated.

Specific urokinase receptors have been described in several cell lines (Vassalli et al., 1985; Stoppelli et al., 1985) and receptor binding has been shown to be species specific (Huarte et al., 1987; Estreicher et al.,
Commercial human urokinase (A) or the serum-free conditioned medium collected from clone 7 of pSV2-uPA transfected B16-F1 cells (B) was applied to the Con A column. The columns were washed with Tris buffer and then same buffer containing \textit{alpha}-methyl-D-mannoside (arrow). Each fraction was collected and assayed for human urokinase by the ELISA using monoclonal antibody to human urokinase.
Since human urokinase is produced by the transfected murine cells, the ability of human urokinase to bind to murine cell surface receptors was studied by a competitive binding assay. Cells were treated with mild acid to unmask cell surface receptor sites and assayed for the receptor binding with $^{125}$I labeled human urokinase in the presence of different concentrations of unlabeled human urokinase. The results (Figure 15) showed that the human urokinase binds to a human cell line PC-3-Met (Kozlowski et al., 1984), derived from a human prostate carcinoma. In contrast, the human urokinase showed no specific affinity to the cell surface of the murine Bl6-F1 cells. This result demonstrates that the human urokinase does not bind to the cell surface of murine Bl6-F1 cells.

**Determination of Urokinase Activity**

It was of interest to measure the increase in plasminogen activator activity, due to the transfection of pSV2-uPA, over the endogenous murine plasminogen activator activity which is normally produced by Bl6-F1 cells. The activity was determined with a chromogenic substrate for plasmin which is generated from plasminogen by the urokinase secreted from the transfected cells. Figure 16
Figure 15. Specific binding of human urokinase to human PC3-Met and murine B16-F1 cells

Binding of human urokinase (uPA) to the human PC3-Met cell surface (○) and the murine B16-F1 cell surface (□) was determined by receptor binding assay. Cells were treated with mild acid to unmask the receptors on the cell surface. PC3-Met and B16-F1 cells were incubated with $^{125}\text{I}$-labeled human urokinase and different concentration of unlabeled human urokinase. Cells were washed with PBS/BSA and lysed with detergent. Lysed cells were counted in a gamma-counter. Nonspecific binding was determined in the presence of excess (50 nM) unlabeled human urokinase and subtracted from the each experimental value. Data are expressed as the mean of triplicate determinations and standard deviations of the mean. The human urokinase appears to specifically bind only to the human PC3-Met cells, but not murine B16-F1 cells.
Figure 16. Secreted plasminogen activator activity of B16-F1 and pSV2-uPA transfected B16-F1 cells as determined against a chromogenic substrate

B16-F1, B16-F10 or transfected B16-F1 cell conditioned media were incubated with the plasmin specific chromogenic substrate S-2251 (H-D-Val-Leu-Lys-p-nitroanilide) and DFP treated plasminogen. After the incubation, the p-nitroaniline absorbance, corresponding to substrate hydrolysis by plasmin which was activated from plasminogen by urokinase produced from conditioned media, was measured. Nonspecific activity was measured in the absence of cell conditioned media and subtracted from the experimental value. Plasminogen activator activity was expressed in pg secreted to conditioned medium per cell per hour.
and Table 2 shows an increase in secreted plasminogen activator activity of 3 to 4-fold in clones 7 and 10 over cells transfected with pSV2-neo alone or untransfected B16-F1 cells. Three to four fold increase in clone 7 and 10 raises the plasminogen activator activity to the level present in the more highly metastatic B16-F10 cell line. The result also shows that transfection of pSV2-neo did not affect urokinase production in B16-F1 cells. Most of cells used for the assay were passaged five to seven times.

The results of the synthetic substrate assay were confirmed by $^{125}$I-fibrin assay for plasmin (Figure 17 and Table 3). In this assay, the plasminogen activator activity was determined by measuring degradation of fibrin those shown in Figure 16 and Table 2 were obtained by $^{125}$I-fibrin plate assay.

From the ELISA data of Table 1, two clones (clones 9 and 12) that produce the least amount of human urokinase and two clones (clones 8 and 18) that produce the highest amount of human urokinase (excluding clone 7 and 10) were selected for further study. The plasminogen activator activity was determined with a chromogenic substrate for plasmin for the clones 8, 9, 12, and 18 and compared to that of clone 7 or pSV2-neo transfected B16-F1 cells. The
Table 2. Quantification of secreted plasminogen activator (PA) activity of B16-F1, B16-F10, and transfected B16-F1 cells by chromogenic substrate assay

<table>
<thead>
<tr>
<th>Cell</th>
<th>Secreted PA activityb (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F1</td>
<td>3.90 ± 0.36c,d</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>4.42 ± 0.54c,e,f</td>
</tr>
<tr>
<td>B16-F10</td>
<td>11.9 ± 1.06d</td>
</tr>
<tr>
<td>Clone 7 (pSV2-uPA)</td>
<td>13.1 ± 0.98e,g</td>
</tr>
<tr>
<td>Clone 10 (pSV2-uPA)</td>
<td>12.1 ± 2.29f,g</td>
</tr>
</tbody>
</table>

aCell conditioned media collected from B16-F1, B16-F10, and B16-F1 transfected cells with pSV2-neo or pSV2-uPA (clone 7 and clone 10) were incubated for 16 hours with the plasmin specific chromogenic substrate S-2251 (H-D-Val-Leu-Lys-p-nitroanilide) and DFP treated plasminogen. After the incubation, the p-nitroaniline absorbance, corresponding to substrate hydrolysis by plasmin, was measured.

bPlasminogen activator activity is expressed in 1x10^-2 pg secreted to conditioned medium per cell per hour.

cNot significantly different (p = 0.11)

dSignificantly different (p = 0.000)

eSignificantly different (p = 0.000)

fSignificantly different (p = 0.000)

gLNot significantly different (p = 0.25)
Figure 17. Secreted plasminogen activator activity of B16-F1 and pSV2-uPA transfected B16-F1 cells as determined by $^{125}$I-fibrin plate assay

Conditioned media from B16-F1, B16-F1 pSV2-neo transfected, B16-F10, clone 7 and clone 10 of B16-F1 pSV2-uPA transfected cells were incubated with DFP-treated plasminogen in $^{125}$I-fibrin plate. The ability of plasmin, which was activated from plasminogen by the urokinase produced from conditioned media, was measured by the released soluble $^{125}$I-fibrin degradation product. Nonspecific activity was measured in the absence of cell conditioned media and subtracted from the experimental value. Plasminogen activator activity was expressed in pg secreted to conditioned medium per cell per hour.
Table 3. Quantification of secreted plasminogen activator (PA) activity of B16-F1, B16-F10, and transfected B16-F1 cells as determined by $^{125}$I-fibrin plate assay

<table>
<thead>
<tr>
<th>Cell</th>
<th>Secreted PA activity(^b) (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F1</td>
<td>4.02 ± 0.24(^c,d)</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>4.81 ± 0.18(^c,e,f)</td>
</tr>
<tr>
<td>B16-F10</td>
<td>11.6 ± 0.67(^d)</td>
</tr>
<tr>
<td>Clone 7 (pSV2-uPA)</td>
<td>11.7 ± 0.45(^e,g)</td>
</tr>
<tr>
<td>Clone 10 (pSV2-uPA)</td>
<td>10.8 ± 0.39(^f,g)</td>
</tr>
</tbody>
</table>

\(^a\)Cell conditioned media collected from B16-F1, B16-F10, and B16-F1 transfected cells with pSV2-neo or pSV2-uPA (clone 7 and clone 10) were incubated with DFP-treated plasminogen in $^{125}$I-fibrin plate. The ability of plasmin, which was activated from plasminogen by the plasminogen activator produced from conditioned media, was measured by the released soluble $^{125}$I-fibrin degradation product.

\(^b\)Plasminogen activator activity is expressed in $1 \times 10^{-2}$ pg secreted to conditioned medium per cell per hour.

\(^c\)Not significantly different (p = 0.30)

\(^d\)Significantly different (p = 0.000)

\(^e\)Significantly different (p = 0.000)

\(^f\)Significantly different (p = 0.000)

\(^g\)Not significantly different (p = 0.52)
results in Table 4 show clones 8 and 18 secreted the same amount of plasminogen activator activity as clone 7. Clones 9 and 12 also secreted the same amount of plasminogen activator activity as pSV2-neo transfected cells. The difference in enzyme activity between clones 8 and 18 and clones 9 and 12 indicates that the increased secretion of plasminogen activator activity of clones 7 and 10 is due to the human urokinase expression of the transfected clones.

To test the stability of the urokinase gene expression, the chromogenic assay was performed with the to soluble peptides by plasmin which was activated from plasminogen by the secreted urokinase. Results similar to conditioned medium collected from the C7 passaged more than 20 times in cell culture. The urokinase activity from that particular sample was similar to those of early passaged cells (data not shown).

**In vivo Metastasis Assay**

This assay assesses the effect of the secreted human urokinase from B16-F1 pSV2-uPA transfected cells on lung colonization, which measures tumor cell extravasation from the blood and then growth into pulmonary tumors.
Table 4. Quantification of secreted plasminogen activator (PA) activity of pSV2-uPA transfected B16-F1 cells (clones 7, 8, 9, 12 and 18) by chromogenic substrate assay

<table>
<thead>
<tr>
<th>Cell</th>
<th>Secreted PA activityb (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clone 7</td>
<td>6.42 ± 1.61c,d,e,f</td>
</tr>
<tr>
<td>Clone 8</td>
<td>6.06 ± 0.60c,d,e</td>
</tr>
<tr>
<td>Clone 9</td>
<td>2.90 ± 0.22g</td>
</tr>
<tr>
<td>Clone 12</td>
<td>2.89 ± 0.24h</td>
</tr>
<tr>
<td>Clone 18</td>
<td>6.02 ± 0.75c,d,f</td>
</tr>
<tr>
<td>B16-F1</td>
<td>2.49 ± 0.59c</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>2.84 ± 0.46g,h</td>
</tr>
</tbody>
</table>

aCell conditioned media collected from 1 x 10^6 B16-F1 transfected cells with pSV2-neo or pSV2-uPA (clone 7, 8, 9, 12 and 18) for 24 hours in 10 mm petri dishes were incubated for 16 hours with the plasmin specific chromogenic substrate S-2251 and DFP treated plasminogen. After the incubation, the p-nitroaniline absorbance, corresponding to substrate hydrolysis by plasmin, was measured.

bPlasminogen activator activity is expressed in 1x10^-2 pg secreted to conditioned medium per cell per hour.

cClones 7, 8, and 18 are different from B16-F1 at p = 0.000.

dClones 7, 8, and 18 are different from B16-F1 (pSV2-neo) at p = 0.000.

eNot significantly different (p = 0.35)

fNot significantly different (p = 0.41)

gSignificantly different (p = 0.009)

hSignificantly different (p = 0.015)
C57BL/6 mice were tail vein injected with 100,000 tumor cells from clones 7, clone 10, or control cells. The control cells transfected with pSV2-neo only, were made up of a mixture of cells from randomly selected pSV2-neo transfected clones, so as not to bias the controls in any one direction. Cells injected into the animal had been passaged 4 to 5 times in cell culture following the transfection. Thirteen mice each, were used for each control or experimental group, in every experiment. Attention was given to the cell culture conditions, such as confluency of the cells, and number of passages which were kept identical for both control and experimental cells in each experiment. To assess the metastatic potential of transfected cells, the number of lung tumors which appeared on the lung surface were counted under the dissecting microscope. An earlier study compared the results of microscopic examination of lung section to the observation of lung surface tumors and found a close correlation between the two results (Wexler, 1966).

Table 5 compares the number of metastatic tumors formed in the lungs of C57BL/6 mice. The pSV2-neo transfected cell mixture had a similar lung colonization ability to that previously reported for untransfected B16-F1 cells (Fidler, 1983). Thus transfection alone does not
Table 5. Lung Colonization by B16-F1 Murine Melanoma Cells Transfected with Human Preprourokinase cDNA in a SV40 Expression Vector

<table>
<thead>
<tr>
<th>Vector</th>
<th>Number of Tumors</th>
<th>Mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Experiment 1</strong></td>
</tr>
<tr>
<td>pSV2-neo</td>
<td>1,1,2,3,3,3,4,4,4,4,9, 11,15</td>
<td>4.92 ± 1.16b</td>
</tr>
<tr>
<td>(control)</td>
<td></td>
<td><strong>Experiment 2</strong></td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA</td>
<td>26,55,58,59,60,84,87,92, 99,102,112,137,172</td>
<td>87.9 ± 10.7b</td>
</tr>
<tr>
<td>(Clone 7)</td>
<td></td>
<td><strong>Experiment 1</strong></td>
</tr>
<tr>
<td>pSV2-neo</td>
<td>2,3,7,7,10,10,14,14,16, 21</td>
<td>10.5 ± 1.88b</td>
</tr>
<tr>
<td>(control)</td>
<td></td>
<td><strong>Experiment 2</strong></td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA</td>
<td>8,25,27,28,28,30,31,39, 45,58,59,96</td>
<td>39.5 ± 6.59b</td>
</tr>
</tbody>
</table>

Animals were injected i.v. in the tail vein with 100,000 B16-F1 transfected cells. Mice were killed 17 days after the injection and the number of lung metastatic foci was counted.

Different at p < 0.001 by both the Mann Whitney U-Test (nonparametric rank sum test) and Student t-test.
appear to significantly increase the metastatic potential of the B16-F1 cells. However, both clones 7 and 10, which were selected for their high secretion of human urokinase, showed a dramatic and significant ($p < 0.001$) increase in lung colonization ability compared to controls.

To confirm our finding that the increased plasminogen activator activity due to the production of urokinase enhanced metastatic potential for clones 7 and 10, clones 8 and 12 were also tested for lung colonization. Clones 8 and 12 were selected for their high and low secretion of human urokinase respectively even though they were transfected with the same vectors, pSV2-uPA and pSV2-neo. The results in Table 6 compare the number of metastatic tumors formed by clones 8 and 12. Clone 8 showed a significant ($p = 0.0019$) increase in lung colonization ability compared to clone 12.

Figure 18 shows typical lungs dissected from control mice which were injected with pSV2-neo transfected B16-F1 cells and experimental mice which received tumor cells from clone 7. Tumors from experimental mice are shown to be mixture of amelanotic and melanotic while tumors from control mice are mainly melanotic. All tumors from the control mice and experimental mice were divided into melanotic or amelanotic groups and the number of
**Table 6. Lung Colonization by B16-F1 cells transfected with pSV2-uPA and pSV2-neo (clone 8 and 12)**

<table>
<thead>
<tr>
<th>Vector</th>
<th>Number of Tumors</th>
<th>Mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (clone 12)</td>
<td>12,34,46,74,94,98,101, 132,144,151</td>
<td>88.6 ± 14.9&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (Clone 8)</td>
<td>119,128,142,181,185, &gt;300,&gt;300,&gt;300</td>
<td>206.9 ± 28.5&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Animals were injected i.v. in the tail vein with 100,000 B16-F1 transfected cells. Mice were killed 17 days after the injection and the number of lung metastatic foci was counted.

<sup>b</sup>Different at p = 0.0019 by Student t-test and p < 0.01 by the Mann Whitney U-Test (nonparametric rank sum test).
Figure 18. Gross appearance of typical lungs dissected from control (left) and experimental (right) mice

Control mice were injected with $10^5$ B16-F1 cells transfected with pSV2-neo and experimental mice received $10^5$ clone 7 cells transfected with the pSV2-neo and pSV2-uPA plasmids.
tumors in each group were counted. Table 7 shows the percent of tumors in the two different color groups. It was observed that high urokinase secreting clones (clones 7, 10, and 8) produced predominantly amelanotic tumors while pSV2-neo transfected clones or low urokinase secreting clone (clone 18) produced mainly melanotic tumors.

Cytotoxicity assay was performed to test if murine cells that produce human urokinase might generate any immunologic response in C57BL/6 mice. The $^{51}$Cr release result shows no indication of immunological response against the human urokinase produced by transfected murine cells (data not shown). (Assay was carried out by the clinical laboratory staff in Dr. John Clancy’s lab., Department of Anatomy).

Spontaneous metastasis from foot pad tumor formed by clone 7 cells was assayed to study the effect of secreted urokinase on the full metastatic process. Table 8 shows the number of pulmonary tumors formed in the spontaneous metastasis experiment from primary tumors grown in the hind leg foot pad of C57BL mice. Clone 7 cells demonstrated an absolute ability to metastasize (all experimental mice showed spontaneous metastasis), while foot pad tumors produced by control B16-F1 pSV2-neo
Table 7. Color distribution of metastatic tumors in murine lung from mice tail-vein injected with B16-F1 transfected cells\textsuperscript{a}

<table>
<thead>
<tr>
<th>Cells Injected</th>
<th>Percentage of tumors in color category (Mean ± S.D.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Melanotic</td>
</tr>
<tr>
<td>pSV2-neo (control)</td>
<td>97.1 ± 6.98</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (C7)</td>
<td>29.4 ± 6.85</td>
</tr>
<tr>
<td>pSV2-neo (control)</td>
<td>93.1 ± 8.57</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (C10)</td>
<td>37.7 ± 8.79</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (C12)</td>
<td>91.0 ± 4.84</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-uPA (C8)</td>
<td>7.66 ± 4.26</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Color of the lung tumors from control and experimental groups were divided into two groups, melanotic and amelanotic and tumor numbers were counted. Results are expressed in percent ± S.E. of tumor numbers in the different color groups.
Table 8. Spontaneous pulmonary metastasis by B16-F1 Murine Melanoma Cells Transfected with Human Preprourokinase cDNA in a SV40 Expression Vector\textsuperscript{a}

<table>
<thead>
<tr>
<th>vector</th>
<th>number of colonies</th>
<th>mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSV2-neo (control)</td>
<td>0,0,0,0,0,0,0,0,2,11</td>
<td>1.18 ± 1.00\textsuperscript{b}</td>
</tr>
<tr>
<td>pSV2-neo + pSV2-uPA (Clone 7)</td>
<td>1,1,2,2,3,3,3,7,11,23, 26,33</td>
<td>9.58 ± 3.26\textsuperscript{b}</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Mice were injected subcutaneously into a footpad with 100,000 cells of transfected cells. Three weeks later, tumor-bearing foot was amputated. Seven weeks after the injection, animals were killed and the number of lung metastatic foci were counted.

\textsuperscript{b}Different at p < 0.001 by the Mann Whitney U-Test (nonparametric rank sum test) and at p < 0.03 by the Student t-test.
transfected cells showed a low ability to spontaneously metastasize (only 2 mice out of 11 showed pulmonary tumors).

**Demonstration of Human Urokinase Activity in Murine Lung Tumors**

To determine the presence of human urokinase produced by the pSV2-uPA transfected cells in murine lung metastatic tumors of clone 7, cells from the lung nodules were plated *in vitro* and assayed for the human urokinase by ELISA using monoclonal antibody. The ELISA results in Table 9 shows that clone 7 cells passaged through animal secreted similar amount of human urokinase as the original clone 7 cells. The plasminogen activator activity from both cells also was measured by chromogenic substrate assay. Table 10 shows that clone 7 cells, either primary or passaged through animal, secreted similar amounts of plasminogen activator activity. Taken together, these results indicate that the plasminogen activator activity detected in the lung nodules is contributed by the human urokinase from the pSV2-uPA transfected cells and that the phenotype of transfected cells was stable *in vivo*. 
Table 9. Quantification of human urokinase production by B16-F1 transfected cells and the same cells passaged through animal (PTA) by ELISA

<table>
<thead>
<tr>
<th>Cell</th>
<th>Absorbance (Mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>0.01 ± 0.01&lt;sup&gt;b,d,f&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo) PTAC&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.01 ± 0.01&lt;sup&gt;b,d,g&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F1 (pSV2-uPA) C7</td>
<td>0.58 ± 0.05&lt;sup&gt;e,f&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F1 (pSV2-uPA) C7 PTAC&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.63 ± 0.06&lt;sup&gt;e,g&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>The secretion of urokinase from each colony was quantitated by IMUCLONE uPA ELISA Kit (American Diagnostica Inc.) on conditioned media taken from the cells incubated in the serum free media for 40 hours.

<sup>b</sup>Value equal to zero as no human urokinase is produced by murine B16-F1 cells which was transfected with the pSV2-neo plasmid.

<sup>c</sup>The lung tumors removed from the mice which were injected with the transfected cells were plated in vitro and cultured for the assay.

<sup>d</sup>Not significantly different (p = 0.49)

<sup>e</sup>Not significantly different (p = 0.30)

<sup>f</sup>Significantly different (p = 0.000)

<sup>g</sup>Significantly different (p = 0.000)
Table 10. Quantification of secreted plasminogen activator (PA) activity of transfected cells and the cells passaged through animal (PTA) by chromogenic substrate assay

<table>
<thead>
<tr>
<th>Cell</th>
<th>Secreted PA activity $^b$ (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>2.49 ± 0.60$^d,f$</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo) PTA$^c$</td>
<td>2.84 ± 0.46$^d,g$</td>
</tr>
<tr>
<td>Clone 7 (pSV2-uPA)</td>
<td>6.42 ± 1.61$^d,e,f$</td>
</tr>
<tr>
<td>Clone 7 (pSV2-uPA) PTA$^c$</td>
<td>6.71 ± 1.73$^d,e,g$</td>
</tr>
</tbody>
</table>

$^a$Cell conditioned media collected from $1 \times 10^6$ B16-F1 pSV2-neo, B16-F1 pSV2-neo and pSV2-uPA (clone 7) transfected cells, and the same cells passaged through animal (PTA) for 24 hours in 10 mm petri dishes were incubated for 16 hours with chromogenic substrate S-2251 and DFP treated plasminogen. After the incubation, the p-nitroaniline absorbance, corresponding to substrate hydrolysis by plasmin, was measured.

$^b$Plasminogen activator activity is expressed in $1\times10^{-2}$ pg secreted to conditioned medium per cell per hour.

$^c$The lung tumors removed from the mice which were injected with the above cells were plated in vitro and cultured for the assay.

$^d$Not significantly different ($p = 0.29$)

$^e$Not significantly different ($p = 0.67$)

$^f$Not significantly different ($p = 0.90$)

$^g$Not significantly different ($p = 0.85$)
II. Inhibition of Urokinase Production in Murine B16-F10 Melanoma Cells and the Study of its Effect on Lung Colonization

Expression of Antisense Human Urokinase Gene

The plasmid pSV2-ASuPA containing 5’ end of 265-base-pair of preprourokinase sequence in an antisense direction with respect to SV40 early gene promoter was prepared from the the plasmid pSV2-dhfr and pRdzbuktt as shown in Figure 7. In the synthesis of pSV2-ASuPA, the ligation on HindIII sites of pSV2-dhfr digest and 265 base-pair of human urokinase cDNA automatically brings the pSV2-ASuPA in an antisense orientation. The final pSV2-ASuPA plasmid construction which is shown in Figure 8 was confirmed by restriction endonuclease digestion map.

Murine B16-F10 melanoma cells of high metastatic potential were similarly cotransfected with the plasmids pSV2-ASuPA and pSV2-neo in 10:1 ratio, glycerol shocked, and grown in the presence of Geneticin (G-418). The surviving colonies were assayed for the production of urokinase by a filter immunoblot assay using a polyclonal antibody to human urokinase as shown in Figure 19. It has been shown that polyclonal antibody to human urokinase
Figure 19. Filter immunoblot analysis of transfected B16-F10 cell colonies

B16-F10 cells were transfected with pSV2-neo (top) or cotransfected with pSV2-ASuPA and pSV2-neo (bottom). Transfected cells were cultured in MEM supplemented with 10% heat inactivated FBS containing Geneticin (G-418). Five weeks later, nitrocellulose membrane filters were placed over the cell colonies to absorb urokinase being secreted. The filters were treated with rabbit polyclonal antibody to human urokinase followed by goat anti-rabbit IgG conjugated with alkaline phosphatase, which were reacted with NBT/BCIP to give dark purple color development corresponding to urokinase presence. Fifteen colonies that show light purple color which indicates lower production of urokinase were selected for further study.
The incorporation of γδVγδ8 and γδVδ8 into the cell culture medium was selected by a chromogenic plasminogen activator assay. The secreted Le assay has been shown to be a useful method for cloning clones. Close examination of the population of cells revealed the presence of γδVδ8 and γδVγδ8.
cross reacts with mouse urokinase (Ossowski, 1988). Fifteen colonies that demonstrated light purple color indicating decreased amounts of urokinase secretion were selected, transferred to separate petri dishes, and expanded in MEM supplemented with 10% heat inactivated FBS.

**Determination of Urokinase Production**

The secretion of urokinase activity into the cell culture medium from the fifteen antisense colonies selected by filter immunoblot assay were quantitated by a chromogenic substrate assay following the activation of plasminogen to plasmin. Table 11 shows that antisense clones 8, 10, 11, and 12 (AC8, AC10, AC11, and AC12) secreted lower amounts of urokinase than other clones. The secretion of urokinase activity of these four antisense clones was confirmed by $^{125}$I-fibrin plate assay as shown in Figure 20 and Table 12. Of four antisense clones, clone 10 (AC10) and clone 8 (AC8) secreted approximately 70% of urokinase when compared to a mixed population of B16-F10 or pSV2-neo transfected B16-F10 cells.

The incorporations of pSV2-ASuPA and pSV2-neo
Table 11. Quantification of secreted plasminogen activator activity from B16-F10 transfected cells by chromogenic substrate assay\textsuperscript{a}

<table>
<thead>
<tr>
<th>Clone No</th>
<th>Absorbance (Mean ± SD)</th>
<th>Clone No</th>
<th>Absorbance (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC1</td>
<td>0.51 ± 0.03</td>
<td>AC9</td>
<td>0.58 ± 0.06</td>
</tr>
<tr>
<td>AC2</td>
<td>0.56 ± 0.04</td>
<td>AC10</td>
<td>0.36 ± 0.02</td>
</tr>
<tr>
<td>AC3</td>
<td>0.46 ± 0.02</td>
<td>AC11</td>
<td>0.46 ± 0.03</td>
</tr>
<tr>
<td>AC4</td>
<td>0.56 ± 0.03</td>
<td>AC12</td>
<td>0.45 ± 0.02</td>
</tr>
<tr>
<td>AC5</td>
<td>0.49 ± 0.01</td>
<td>AC13</td>
<td>0.68 ± 0.04</td>
</tr>
<tr>
<td>AC6</td>
<td>0.70 ± 0.04</td>
<td>AC14</td>
<td>0.61 ± 0.03</td>
</tr>
<tr>
<td>AC7</td>
<td>0.47 ± 0.02</td>
<td>AC15</td>
<td>0.59 ± 0.02</td>
</tr>
<tr>
<td>AC8</td>
<td>0.40 ± 0.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B16-F10</td>
<td>0.51 ± 0.02</td>
<td>B16-F10Neo</td>
<td>0.52 ± 0.03</td>
</tr>
</tbody>
</table>

\textsuperscript{a}B16-F10 or transfected B16-F10 cell conditioned media were incubated for 16 hours with the plasmin specific chromogenic substrate S-2251 (H-D-Val-Leu-Lys-p-nitroanilide) and DFP treated plasminogen. After the incubation, the p-nitroanilide absorbance, corresponding to substrate hydrolysis by plasmin, was measured.
Figure 20. Secreted plasminogen activator activity of B16-F10 and pSV2-ASuPA transfected B16-F1 cells determined by $^{125}$I-fibrin plate assay

Conditioned media from B16-F10, B16-F10 transfected with pSV2-neo, antisense clones 8 (AC8), 10 (AC10), 11 (AC11), and 12 (AC12) of transfected with pSV2-ASuPA were incubated with DFP-treated plasminogen in $^{125}$I-fibrin plate. The activity of plasmin, which was activated from plasminogen by the urokinase produced from conditioned media, was measured by the released soluble $^{125}$I-fibrin degradation product. Nonspecific activity was measured in the absence of cell conditioned media and subtracted from the experimental value. Plasminogen activator activity was expressed in pg secreted to conditioned medium per cell per hour.
Table 12. Quantification of secreted plasminogen activator (PA) activity of B16-F10 and transfected B16-F10 cells as determined by $^{125}$I-fibrin plate assay$^a$

<table>
<thead>
<tr>
<th>Cell</th>
<th>Secreted PA activity$^b$ (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F10</td>
<td>12.0 ± 0.37$^e$</td>
</tr>
<tr>
<td>B16-F10 (pSV2-neo)</td>
<td>11.9 ± 0.83$^e$</td>
</tr>
<tr>
<td>AC8 (pSV2-ASuPA)</td>
<td>8.33 ± 0.59$^{c,d}$</td>
</tr>
<tr>
<td>AC10 (pSV2-ASuPA)</td>
<td>8.71 ± 0.71$^{c,d}$</td>
</tr>
<tr>
<td>AC11 (pSV2-ASuPA)</td>
<td>9.34 ± 0.46$^{c,d}$</td>
</tr>
<tr>
<td>AC12 (pSV2-ASuPA)</td>
<td>9.60 ± 0.37$^{c,d}$</td>
</tr>
</tbody>
</table>

$^a$Cell conditioned media collected from B16-F10 and pSV2-neo or pSV2-ASuPA transfected B16-F10 cells were incubated with DFP-treated plasminogen in $^{125}$I-fibrin plate. The ability of plasmin, which was activated from plasminogen by the plasminogen activator produced from conditioned media, was measured by the released soluble $^{125}$I-fibrin degradation product.

$^b$Plasminogen activator activity is expressed in $1 \times 10^{-2}$ pg secreted to conditioned medium per cell per hour.

$^c$AC8, AC10, AC11, and AC12 are significantly different from B16-F10 at $p = 0.008$, 0.0022, 0.0016, and 0.0014 respectively.

$^d$AC8, AC10, AC11, and AC12 are significantly different from B16-F10 (pSV2-neo) at $p = 0.0037$, 0.0031, 0.0095, and 0.0012 respectively.

$^e$Not significantly different ($p = 0.95$)
plasmids into the B16-F10 cell genomic DNA of antisense clones 10 and 8 were assayed by Southern blot hybridization assay as shown in Figure 21. The DNAs were prepared from the antisense clones 10 and 8 and pSV2-neo transfected cells. To detect the pSV2-neo and pSV2-ASuPA incorporation, DNAs were digested with PstI, separated by electrophoresis, transferred to nitrocellulose filter, and probed with $^{32}$P-labeled HpaI-PstI pSV2-ASuPA fragment. The digestion of pSV2-ASuPA with PstHI generates four DNA bands with base pairs of 2418, 1430, 958, and 923 pairs and $^{32}$P-labeled probe hybridizes with all the band. The digestion of pSV2-neo with PstI generates two DNA bands with base pairs of 3540 and 958 and the probe hybridizes with both bands. Figure 21 shows that antisense clones AC10 and AC8 demonstrate the restriction endonuclease digested bands identical to those of pSV2-ASuPA plasmid. The densitometer scan of autoradiographs (data not shown) suggests less than 5 copy numbers of pSV2-ASuPA were present in the transfected antisense clones 10 or 8 cells.

**Lung Colonization Assay**

To assess the effect of inhibition of urokinase production on lung colonization, antisense clones 10 and 8
Figure 21. Southern blot hybridization analysis of DNA isolated from antisense clones 10 (AC10) and 8 (AC8) of pSV2-ASuPA transfected cells, B16-F10, and B16-F10 pSV2-neo transfected cells

DNAs were isolated from antisense clone 10 (AC10) and 8 (AC8) of pSV2-ASuPA transfected B16-F10 cells, pSV2-neo transfected cells, or untransfected B16-F10 cells. The DNAs (10 ug) were cleaved with PstI and electrophoresed through 0.8% agarose gel. A control pSV2-ASuPA plasmid preparation was similarly digested with PstI and different amounts were loaded onto the same gel. The DNAs were transferred to nitrocellulose and probed with $^{32}$P-labeled HpaI-PstI fragment of pSV2-ASuPA. Lanes 1 and 2 contain DNA made from $7 \times 10^6$, and $3.5 \times 10^6$ cells AC10. Lanes 3 and 4 contain DNA made from $7 \times 10^6$ and $3.5 \times 10^6$ cells of AC8. Lane 5 contain DNAs made from $7 \times 10^6$ cells of untransfected B16-F10 and lane 6 from $3.5 \times 10^6$ of pSV2-neo transfected cells. Lanes 7, 8, and 9 contain pSV2-ASuPA DNA of 10, 5, 2 ng respectively.
were injected to mice through tail vein. Table 13 shows the results of the lung colonization assay of antisense clones 10 and 8. AC10 and AC8 cells which produced approximately 70% of urokinase compared to B16-F10 cells showed a 40 to 42% decrease in the ability to form lung tumors \( p = 0.0016 \) and \( 0.0019 \) respectively by Student’s t test and \( p < 0.005 \) and \( p < 0.005 \) by the Mann Whitney U-test respectively. The pSV2-neo transfected B16-F10 cell mixture showed a similar lung colonization ability compared to untransfected B16-F10 cells (Fidler, 1983). Thus, as shown in B16-F1 cell transfection, transfection alone does not affect metastatic potential of the B16-F10 cells.

Figure 22 shows the gross appearance of typical lungs dissected from control mice (injected with pSV2-neo transfected cells) and experimental mice (injected with pSV2-neo and pSV2-ASuPA transfected cells). It was observed the majority of tumors from the control mice were smaller than that from the experimental mice. Thus, all the tumors from the control and experimental mice were grouped into three different sizes (small, medium, and large) and number of tumors in each size category were counted. Small size tumor indicates less than 0.2 mm, medium size between 0.2 mm and 0.7 mm, and large size more
Table 13. Lung colonization by B16-F10 murine melanoma cells transfected with human preprourokinase antisense gene in a SV40 expression vector\(^a\)

<table>
<thead>
<tr>
<th>Vector</th>
<th>Number of Tumors</th>
<th>Mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Experiment 1**

<table>
<thead>
<tr>
<th>Vector</th>
<th>Number of Tumors</th>
<th>Mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSV2-neo (control)</td>
<td>32,34,55,56,71,76,80,90,91,92,97,99</td>
<td>72.8 ± 6.8(^b)</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-ASuPA (AC10)</td>
<td>27,28,28,29,33,34,37,40,45,45,60,67,86</td>
<td>43.0 ± 4.9(^b)</td>
</tr>
</tbody>
</table>

**Experiment 2**

<table>
<thead>
<tr>
<th>Vector</th>
<th>Number of Tumors</th>
<th>Mean ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSV2-neo (control)</td>
<td>116,136,148,155,189,192,245,254,275,306,321</td>
<td>212.5 ± 21.5(^c)</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-ASuPA (AC8)</td>
<td>51,71,73,101,126,135,150,152,156,166,173</td>
<td>123.1 ± 12.8(^c)</td>
</tr>
</tbody>
</table>

\(^a\)Animals were tail vein injected with \(1\times10^5\) B16-F10 transfected cells. Mice were killed 17 days later and number of lung metastatic foci was counted.

\(^b\)Different at \(p = 0.0016\) by Student t-test and \(p < 0.01\) by the Mann Whitney U-test (nonparametric rank sum test).

\(^c\)Different at \(p = 0.0019\) by Student t-test and \(p < 0.01\) by the Mann Whitney U-test.
Figure 22. Gross appearance of typical lungs dissected from control (left) and experimental (right) mice

Control mice were injected with $10^5$ B16-F10 cells transfected with pSV2-neo and experimental mice received $10^5$ antisense clone 10 (AC10) cells transfected with the pSV2-neo and pSV2-ASuPA plasmids.
than 0.7 mm in diameter. Figure 23 and Table 14 shows the size of metastatic tumors in lungs expressed in percent of tumor numbers in the different size categories. It was observed that more than 60% of tumors produced by experimental mice belong to large size category, while B16-F10 pSV2-neo transfected cells produce mainly small and medium size tumors.
Figure 23. Size of metastatic tumors in murine lung from mice tail-vein injected with B16-F10 transfected cells

Size of the lung tumors from control and experimental mice were determined and divided into three categories, small (<0.2 mm in diameter), medium (0.2 mm-0.7 mm), and large (>0.7 mm). Results are expressed in percent of tumor numbers in the different size category.
Table 14. Size of metastatic tumors in murine lung from mice tail-vein injected with B16-F10 transfected cells\(^a\)

<table>
<thead>
<tr>
<th>Cells Injected</th>
<th>Percentage of tumors in size category (Mean ± S.E.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Small</td>
</tr>
<tr>
<td>pSV2-neo (control)</td>
<td>32.8 ± 2.86</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-ASuPA (AC10)</td>
<td>13.9 ± 1.81</td>
</tr>
<tr>
<td>pSV2-neo (control)</td>
<td>37.0 ± 1.86</td>
</tr>
<tr>
<td>pSV2-neo &amp; pSV2-ASuPA (AC8)</td>
<td>11.2 ± 2.27</td>
</tr>
</tbody>
</table>

\(^a\)Size of the lung tumors from control and experimental groups were measured and divided into three size categories, small (<0.2 mm in diameter), medium (0.2 mm-0.7 mm), and large (>0.7 mm). Results are expressed in percent ± S.E. of tumor numbers in the different size category.
CHAPTER V

DISCUSSION

We have shown in this work direct evidence for the importance of urokinase in tumor cell metastasis by modifying the gene expression in murine B16 melanoma tumor cells. The metastatic potential of the cells transfected with preprourokinase cDNA was dramatically enhanced compared to the control cells in vivo. In addition, the cells transfected with antisense cDNA of urokinase gene showed decreased metastatic potential in vivo.

Cell Lines Selected for the Study

B16 melanoma cell lines, B16-F1 and B16-F10, which metastasize to form pulmonary tumor nodules (Fidler, 1973) were used in this study. The B16 tumor lines have been established by Fidler (1973) by injecting tumor cells i.v. into syngeneic C57BL/6 mice, isolating, and then culturing the secondary lung tumor nodules in tissue culture. The B16-F1 cell line was passaged once through the selection
process, while B16-F10 cell line was passaged ten times. The B16-F1 cell line possesses low ability to form metastatic lung colonies, while the B16-F10 cell line shows high ability when injected i.v. into syngeneic C57BL/6 mice (Fidler, 1975). These cell lines have been used by a number of investigators to determine a quantitative correlation between the production of plasminogen activator and their capacity to metastasize. Wang et al. (1980) reported quantitative differences in plasminogen activator production between low metastatic B16-F1 and high metastatic B16-F10 melanoma sublines, the latter producing more plasminogen activator activity than the B16-F1 cells. Nicolson et al. (1976) however showed contradictory results, reporting a lack of correlation in plasminogen activator activities between variant B16 sublines such as B16-F1, B16-F5, B16-F10, and B16-F13.

Expression of Human Urokinase Gene in B16-F1 Melanoma Cells

The DNA-mediated transfection technique (Graham and van der Ed, 1973) was used as a means of introducing foreign genes into the murine melanoma cells. The optimal transfection conditions as described in the Methods
section were developed specifically for B16 cell lines. The human preprourokinase gene was successfully expressed in B16-F1 cells under the control of an SV40 early gene promoter (pSV2 vector). The expression of the incorporated preprourokinase gene was found to be stable. No loss of human prourokinase expression was observed even after over 20 passages of the transfected cells.

The data in Figure 16 and 17 show that clone 7 and clone 10 of pSV2-uPA transfected cells secrete a three to four fold increase in plasminogen activator activity. The enhanced plasminogen activator activity in clone 7 and clone 10 was shown to be specifically related to human urokinase and not to the endogenous murine urokinase based on the following observations: (i) The clones were initially selected based solely on their high production of human urokinase, by a filter immunoblot assay using a polyclonal antibody to human urokinase (Figure 9), (ii) In a second selection, from those clones selected by the filter immunoblot assay, clones 7 and 10 were shown to produce the highest level of human urokinase by ELISA using a monoclonal antibody to human urokinase (Table 1). Further characterization of the selected cells showed: (i) Urokinase produced by clone 7 was glycosylated as expected for the human urokinase (Figure 16). The murine urokinase
is not a glycoprotein (Belin, et al., 1985), (ii) Southern blot hybridization analysis (Figure 10) demonstrated that multiple copies of the human urokinase gene were incorporated in the genomic DNA of clone 7. The human urokinase was selectively identified under the blotting conditions used for the assay. The murine urokinase gene did not hybridize with the human cDNA probe under the conditions used, and, (iii) Northern blot hybridization analysis (Figure 5) demonstrated human urokinase gene expressions by clone 7 and clone 10.

**Glycosylation of Human Urokinase by Murine Cells**

The result of concanavalin A affinity chromatography (Figure 14) demonstrates that the human urokinase, produced by the transfected murine B16-F1 cells, is glycosylated. The murine urokinase gene lacks a glycosylation site (Belin et al., 1985) and is therefore not a glycoprotein. It is not surprising that the human gene product would be glycosylated since human urokinase contains a glycosylation site in its amino acid sequence (Holmes et al., 1985; Ricco et al., 1985). A carbohydrate side chain, containing at least four glucosamine and two galactosamine residues, was reported at asparagine in
position 144 of the human urokinase B chain (Steffens et al., 1982).

Lack of Binding of Human Urokinase to Murine Receptor

As depicted in Figure 15, human urokinase does not bind to cell surface receptor sites on the murine B16-F1 cells. It is not known whether the lack of binding is the result of the glycosylation of human urokinase, or due to the other changes in the structure of the urokinase that prevents the human urokinase from binding to the mouse receptors. The observation that human urokinase does not bind to murine cell receptors is in agreement with other studies that reported a lack of cross-species binding of urokinase to cell surface receptors. Huate et al. (1987) reported no significant binding of human prourokinase to mouse spermatozoa. Most recently, Estreicher et al. (1989) demonstrated that human, mouse, and porcine urokinase bind to the corresponding cell receptors of the same species, while human urokinase failed to bind to murine MSV-3T3 cells and murine urokinase did not bind to human HeLa cells.

Experimental Model for in vivo Metastasis Assay
To assay the metastatic potential of the transfected Bl6-F1 cells expressing the human urokinase gene in vivo, the lung colonization and spontaneous metastasis assays were employed. In the lung colonization assay, mice were i.v. injected through the tail vein, and 2-3 weeks later the animals were sacrificed and tumor nodules on the lung surface were counted under a dissecting microscope (Fidler, 1975). This assay measures tumor cell extravasation from the blood stream, invasion of basement membrane and extracellular matrix, and then growth into pulmonary tumors. In the spontaneous metastasis model, tumor cells injected in the foot pad of the mouse, grow into a primary tumor site and metastasize as secondary tumors to the lung (Fidler, 1978). This assay tests the full metastatic process in which the tumor cells intravasate through the capillary endothelial walls, survive in the circulation, extravasate from the capillaries through the basement membrane, and invade the extracellular matrix to establish a new tumor site.

The Effect of Increased Expression of Urokinase on Lung Colonization Potentials

Three of the clones (clones 7, 8, and 10) among the human preprourokinase transfected Bl6-F1 cells, were
chosen for in vivo metastatic assay. All of them showed a dramatic increase in lung colonization following tail vein inoculation (Table 5 and 6). The ELISA and chromogenic substrate assays for plasminogen activator confirmed the human urokinase activity in the cells from the lung nodules (Table 9 and 10). These results clearly show that the increased lung colonization potential of the clones 7, 8, and 10 is due to the human urokinase produced by the pSV2-uPA transfected cells. Since the cells were solely selected for their ability to secrete human urokinase which does not bind to cell surface receptors, the issue of whether urokinase acts to promote metastasis on the cell surface or at locations away from the surface can be addressed. Our results demonstrate that the increased secretion of human urokinase activity strongly promotes metastasis in vivo. These results are in agreement with those recently reported by Cajot et al. (1989). These authors transfected the human urokinase gene into mouse L cells and showed a correlation between the modulation of prourokinase gene expression and the degradation of extracellular matrix by in vitro invasion through a basement membrane like material, Matrigel. Their results demonstrated that urokinase binding to the cell surface is not required for the increased degradation and invasion of
the extracellular matrix. These authors did not assay their cells in an in vivo model for metastasis. Axelrod et al. (1989) also recently demonstrated that their ras transformed murine NIH3T3 cells, transfected with recombinant human urokinase, produced 30-fold elevation in urokinase activity and manifested an increased invasion rate in an in vitro basement membrane assay. They also showed that the transfected cells had a sixfold increase in pulmonary metastatic lesions after i.v. injection into nude mice.

Other authors however support the hypothesis that cell surface-localized urokinase activity is critical for tumor cell metastasis. Ossowski (1988) demonstrated that a saturation of human tumor cell, HeLa, receptors with exogenous human urokinase enhanced the invasion of the chick embryo chorioallantoic membrane. This suggests that urokinase binding to its receptor is important for the increased invasive potential of the tumor cells. A recent study by Hearing et al. (1988) demonstrated the presence of urokinase activity on the cell surface of B16 melanoma cells by immunofluorescence. The authors also reported that the preincubation of these cells expressing urokinase with an antibody to urokinase caused a reduction in their lung colonization ability when injected through the tail
vein of mice. Based on these data, the authors argued that cell surface localized urokinase activity has a critical role in lung colonization. However, the statistical significance of their data does not appear conclusive. In Table 2 of their report, they tested the effect of urokinase specific antibodies on pretreated B16 cells in 12 separate experiments. Out of 12 experiments, the authors reported that three experiments showed no significant difference between the two groups using Student t test at $p \leq 0.05$. However, by a Wilcoxon non-parametric analysis of their experimental data, only two of the twelve experiments with anti-urokinase pretreated cells showed a significant decrease (at $p \leq 0.05$) in lung colonization as compared to the controls. In our study, we show that the human urokinase does not bind to the murine cell surface receptor, yet it clearly promotes metastasis.

The role of the cell surface urokinase receptors may serve to focus the enzyme activity at critical sites on the cell surface. The binding of urokinase to its receptor, however, may also serve different functions than to promote metastasis. For example, it has been suggested that urokinase may bind to cells and act as a cell mitogen to induce cell proliferation (Kirchheimer et al., 1987;
Takada and Takada, 1989; Kirchheimer et al., 1989).

Regardless of the role of the cell surface associated urokinase, the results in this report show that an increase in the unbound, secreted form of human urokinase dramatically increased spontaneous metastasis and lung colonization by the B16-F1 cells. Future investigation that would help define the role of the urokinase receptor may involve cloning the urokinase receptor gene and its subsequent transfection into B16 cells. Such study would help elucidate the effect of urokinase cell surface receptor binding in invasion and metastasis in vivo.

The lung colonization data of the clones 7, 8, and 10 in Table 5 and 6 and increased urokinase secretion of these clones infer that the increase in lung colonization by B16-F1 cells is directly related to an increased urokinase activity. A comparison of the plasminogen activator activity of B16-F1 cells, B16-F1 pSV2-uPA transfected cells (clone 7 and clone 10), and B16-F10 cells show that the clone 7 cells produce plasminogen activator activity equal to that of the B16-F10 cells (Table 2 and 3). In addition, the lung colonization potential for B16-F10 cells is similar to that observed for the clone 7 cells (Schultz et al., 1988).

A positive correlation between production of
plasminogen activator and a spontaneous metastatic potential for B16-F1 and B16-F10 cells has been previously reported (Wang et al., 1980). This earlier report, however, while showing a correlative increase in plasminogen activator production with increased spontaneous metastasis, was not based on a known increase in the expression of a single specific gene. Multiple differences have been reported between B16-F1 and B16-F10 cells besides the differences in urokinase production. For example, there are differences in membrane lipid composition (Schroeder and Gardiner, 1984), in the expression of a 72 Kd glycosylated protein by B16-F10 cells and not by B16-F1 (Kimura and Xiang, 1986), and in response of lung colonization to the monoclonal antibodies produced to tumor-associated antigens of B16-F1 or B16-F10 cells (Herd, 1987). In addition, B16-F10 cells showed an increased glycosyltransferase activity as compared to B16-F1 counterparts (Bosmann et al., 1974) and B16-F10 cells have a greater propensity to form in vitro aggregates with artificially disaggregated lung cells than B16-F1 cells (Nicolson and Winkelhake, 1975).

The selection of the clones in this study was based solely on the ability of transfected cells to produce secreted human urokinase. The secreted human urokinase in
the B16-F1 cell line is shown to raise the metastatic potential of B16-F1 cells to that of B16-F10. This finding supports the conclusion that increase in urokinase activity is sufficient to explain the difference in metastatic potential between B16-F10 and B16-F1 cells.

Blood-borne metastasis is a multiple step process which may be subdivided into several steps: (i) detachment of malignant tumor cells from the original tumor mass, (ii) invasion through the extracellular matrix and basement membrane with intravasation through the capillary endothelial walls, (iii) travel of tumor cells through the circulation, (iv) arrest in the capillary beds of the target tissue, (v) extravasation from the capillaries through the basement membrane and extracellular matrix, and (vi) implantation and growth of secondary tumor cells at a new site. The most critical steps in the metastatic process, where proteolytic enzymes have a role, appears to be the intravasation and extravasation steps (Liotta et al., 1982).

The hypothesis that urokinase plays an important role in intravasation comes from the earlier work of Ossowski and Reich (1983) who showed that an antibody to human urokinase only inhibited lung colonization in the chick embryo when human tumor cells were placed on the
chorioallantoic membrane. Ossowski (1988) later reported in this model, a lack of urokinase effect on the extravasation step of metastasis by showing that the urokinase antibody did not inhibit metastasis when human tumor cells were directly injected into a chick embryo vein, as opposed to the cells being placed on the chorioallantoic membrane. These experiments support the argument that urokinase is important in the intravasation step, but not in the extravasation step.

The argument of Ossowski agrees with the current interpretation of the role of fibrin in metastasis. It has been argued that coagulation and the formation of microthrombi might promote the attachment of tumor cells to the capillary walls of the target organ, forming a stationary phase of tumor cells which allows time for the extravasation of tumor cells to occur (Dano et al., 1985; Markus et al., 1984; Harvey et al., 1988). Urokinase, which can promote fibrin degradation through plasmin mediated fibrinolysis, would act against the formation of this protective stationary phase. Subsequently high urokinase activity in the extravasation step should lead to a decrease in lung colonization (Markus et al., 1984). In fact, Markus et al. (1983) compared the secretion of urokinase between the primary and metastatic tumors of
different types and found that urokinase secretion by metastatic tumors were lower than those of primary tumors. Harvey et al. (1988) also made similar observations which led to the proposal that reduced secretion of urokinase of metastatic tumors might provide a distinct advantage to tumor cells destined to initiate metastatic foci, and may contribute to the ability of circulating cancer cells to lodge in the blood vessels of the target organs. This hypothesis is also supported by the study of Gunji and Gorelik (1988) who demonstrated that the presence of fibrin deposition on tumor cells protected them from immunological destruction. However, this hypothesis does not agree with other reports. Iwakawa et al. (1986) demonstrated that an anticoagulant, which suppresses coagulation via inhibition of thrombin (which activates fibrinogen to fibrin) increased, rather than decreased, the number of lung colonies after i.v. injection of tumor cells. Ostrowski et al. (1986) reported similar findings that, mice implanted with mini-isopump infusion of a thrombin inhibitor produced increased B16 melanoma lung colonization.

The results of the lung colonization assay (Table 5 and 6) in this study, clearly shows an increase in urokinase activity by the C7, C10, and C8 clones of the
pSV2-uPA transfected cells which caused a dramatic increase in lung colonization ability. The lung colonization assay by tail vein injection (Table 5 and 6) measures the extravasation step of the metastatic process, as the tumor cells are directly injected into the blood, circumventing the earlier steps of the metastatic process. Our conclusion that urokinase is important in the extravasation step of metastasis is consistent with the recent similar observations by Axelrod et al. (1989), that H-ras-transformed NIH3T3 cells expressing high levels of urokinase activity were more efficient in lung that increased plasminogen activator activity in rat mammary adenocarcinoma cells correlated with their lung colonization ability.

The increase in secreted urokinase activity also provided the clone 7 cells with an ability to spontaneously metastasize from a primary tumor in the foot pad (Table 8). The spontaneous metastasis assay measures the ability of tumor cells to intravasate through the capillary endothelial walls, survive in the circulation, extravasate from the capillaries through the basement membrane, and invade the extracellular matrix to establish a new tumor site. These results are in agreement with earlier work by Wang et al. (1980) who demonstrated that
high plasminogen activator production by B16-F10 subline cells contributed to spontaneous metastasis, whereas B16-F1 cells of low plasminogen activator production, had decreased pulmonary metastases.

The increased spontaneous metastatic ability of clone 7 (Table 8) might be due to (i) the increase in the ability of the clone 7 cells to extravasate, as shown by the colonization assay (Table 5), (ii) the acquisition of colonization. Another report that support this hypothesis is the earlier study by Carlsen et al. (1984) which showed an increased ability to intravasate, or (iii) the increase in ability for both intravasation and extravasation. If urokinase activity was essential only in the extravasation step, then the ability of clone 7 to spontaneously metastasize may be simply due to the increased ability to extravasate. Whether the secreted form of urokinase activity is controlling the intravasation as well as the extravasation steps in the metastatic process remains to be clarified. Models that specifically isolate the intravasation step need to be developed in order to determine precisely how urokinase affects this step in the metastatic process.

The cells secreting lower amounts of human urokinase (pSV2-neo transfected B16-F1 or C12 of pSV2-neo
and pSV2-uPA transfected cells) produce predominantly melanotic tumors as shown in Table 7. In contrast, the lung nodules formed by the cells secreting higher amounts of human urokinase consist of mixtures of amelanotic and melanotic tumors. In all three clones (clones 7, 10, and 8) the lesions predominantly demonstrated the amelanotic phenotype.

Phenotypic change cannot be attributed to the pSV2-neo transfection since all the clones contain the pSV2-neo gene. The overproduction of urokinase may be responsible for the expression of this phenotype since the only difference between these groups is the amount of human urokinase secretion. Therefore high amounts of urokinase secretion in B16-F1 cells might inhibited melanin synthesis/production. The absence of the pigment in amelanotic tumor is reported to be the result of deficiency of tyrosinase activity (Slominski et al., 1987; Bennett et al., 1986) even though some investigators reported that tyrosine activity did not correlate in vitro with melanin synthesis in K1735 SW-1 cells (Price et al., 1988).

A possible link between the high urokinase production and the metastatic potential may be the state of differentiation of the B16 cells. It has been
argued that more malignant cells are less differentiated (Bennett et al., 1986). In the B16 melanoma cell lines, melanin formation may correlated with differentiation. Thus amelanotic cells are less differentiated and also more metastatic. Urokinase production may affect the metastatic potential of a cell by changing its state of differentiation. However B16-F10 cells secrete a similar amount of urokinase as C7 cells but produce melanotic lung nodules.

Several reports have linked melanin synthesis with a reduction in tumor cell proliferation (Gray et al., 1964; Lotan and Lotan, 1980). Other investigators have also suggested a positive correlation between tumor cell malignancy and the amelanotic phenotype in B16 cell lines (Romsdahl and Hsu, 1972; Lotan and Lotan, 1980). Our study confirmed these reports by showing that transfected cells secreting human urokinase undergo a phenotypic shift to cells that are more metastatic and form amelanotic colonies.

**The Effect of Inhibition of Urokinase Production in the Lung Colonization Potential**

If urokinase is required for tumor cell
colonization (Table 5 and 6), then the inhibition of urokinase activity should lead to a reduction in metastasis. By transfection of B16-F10 cells with an antisense urokinase gene, it may be possible to evaluate the effects of inhibiting urokinase gene expression on the metastatic process. B16-F10 melanoma cells of high metastatic potential were transfected with a plasmid containing human urokinase in the antisense direction (pSV2-ASuPA). The antisense clones 10 (AC10) and 8 (AC8) cells which produced 30% less urokinase activity were selected (Table 11, 12 and Figure 20). A Southern blot hybridization assay showed the incorporation of the antisense plasmid into the genomic DNA of these cells (Figure 21). Tail vein injection by these two clones showed a 40% reduction in lung colonization (Table 13). These results are in agreement with our previous experiments in which pSV2-uPA transfected clones of B16-F1 cells showed increased urokinase production and increased lung colonization. Taken together these two results give supporting evidence that urokinase has an essential role in extravasation process of lung colonization by B16 melanoma cells. This is in contrast to the results reported in the chorioallantoic membrane experiment which concluded that urokinase does not play a role in the
extravasation step (See previous discussion, Ossowski and Reich, 1983).

The human urokinase gene transfected C7 clone showed that approximately 150 copies of the urokinase gene was incorporated in B16–F1 cell DNA genome. After transfection of the antisense gene (pSV2–ASuPA) with the same SV40 expression vector, a small copy number of antisense urokinase genes were shown to be incorporated in the B16–F10 genomic DNA in the most inhibited cell colony. The difficulty of observing high copy number for incorporation of the antisense gene might be explained by the necessity of urokinase expression for cell viability. Cells with higher copies of incorporated antisense urokinase gene might fail to survive, hence escape detection. It has been proposed that urokinase is a growth stimulant in various cell lines by several investigators (Kirchheimer et al., 1987; Kirchheimer et al., 1989; Tanaka and Tanaka, 1989). Earlier study showed the production of plasminogen activator reached maximum during the logarithmic growth of transformed 3T3 cells and decreased as the cells reach the confluence (Jaken and Black, 1979). It was also shown that the production of urokinase correlated with the proliferative state of the melanoma cells (Grimmaldi et al., 1986).
An attempt to demonstrate antisense mRNA expression by Northern blot hybridization was made. However, it was not possible to detect the antisense transcript in the pSV2-ASuPA transfected cells because of low abundance of antisense mRNAs. A more sensitive assay to demonstrate the presence of the antisense transcript would be to use the polymerase chain reaction (PCR) amplification, following reverse transcriptase treatment, to convert mRNA to cDNA (Saiki et al., 1988).

The variation in the numbers of lung colonies between the control groups in Experiment 1 and 2 did not closely coincide, as is shown in Table 13. This may be the result of the use of different lots of animals or the use of cells from different time period. Since the control group was always tested in identical manner to the experimental group for each experiment, the important consideration for interpreting the data is the relative number of metastases for both control and experimental animals in any one set of experiments carried out at the same time and with the same lot of cells and animals. The variation in average numbers of lung colonies in each of the two separate experiments carried out at different time periods should not affect the conclusions of this work.

Table 14 and Figure 22 and 23 show that the
metastatic lung tumors from the mice injected with antisense clones 10 or 8 were larger than those in control mice containing cells transfected with the pSV2-neo plasmid alone. This result suggests that decreased urokinase production inhibits metastasis but not the growth of tumors.

Future studies to assess the role of urokinase in metastasis would be to regulate urokinase activity by means of plasminogen activator inhibitors (PAIs). Several workers have shown that there are at least three immunologically distinct PAIs, including PAI-1, PAI-2, and protease nexin (Loskutoff et al., 1983; Scott et al., 1985; Sprengers and Kluft, 1987). These proteins inactivate both urokinase and tissue-type plasminogen activators by forming covalent complexes with the active site serine residues of the plasminogen activators (Andreasen et al., 1986). PAI-1 is an efficient inhibitor of both urokinase and tissue plasminogen activators. It has been purified (van Mourik et al., 1984) and its cDNA has been sequenced (Ny et al., 1986). PAI-2, which reacts more rapidly with urokinase than with tissue type plasminogen activator, has also been purified (Astedt et al., 1985) and the full length cDNA sequence has been determined (Ye et al., 1987). Future studies could
transfect cloned PAI-1 and PAI-2 genes into metastatic cells to evaluate their role in metastasis. It could be predicted that PAI-1 and PAI-2 are metastatic suppresser genes, in the same way as TIMP appears to be a metastatic repressor protein (Khokha et al., 1988).
Metastasis is a process in which tumor cells detach from their primary site(s), invade through the surrounding tissue, and give rise to new lesions at sites distant from the primary tumor(s). Urokinase may have an important role in tumor cell metastasis. It has a proteolytic enzyme activity which can promote degradation of extracellular matrix and basement membrane. In this study, the role of urokinase in tumor cell metastasis was examined by modifying the urokinase gene expression in tumor cells.

A SV40 expression vector containing the human preprourokinase gene (plasmid pSV2-uPA) was constructed and cotransfected with a selection marker gene (pSV2-neo) into murine Bl6-F1 melanoma cells of low metastatic potential. The expression of the human urokinase gene was demonstrated by a filter immunoblot assay and an ELISA using a monoclonal antibody to human urokinase. Southern
blot hybridization analysis of the clone expressing the highest level of human urokinase showed that the pSV2-uPA plasmid was incorporated in approximately 150 copies. These cells exhibited a 3 to 4-fold increase in secreted urokinase activity. The human urokinase synthesized by the murine cells was found to be glycosylated. Furthermore, it was shown that human urokinase does not bind to the murine B16-F1 cell surface urokinase receptor sites. Thus the human urokinase is simply constitutively synthesized and secreted by the transfected murine melanoma cells.

In the lung colonization assay which measures tumor cell extravasation from the blood and subsequent pulmonary tumor growth, the pSV2-uPA transfected cells showed a 4 to 18-fold increase in the ability to form lung tumors. In the spontaneous metastatic assay, which measures the full metastatic process, the transfected cells showed an absolute ability to metastasize (12 out of 12 mice), while control cells showed a low ability to metastasize (only 2 out of 11 mice). These results clearly show that an increase in secreted urokinase activity promotes both lung colonization and spontaneous metastasis.

In addition, B16-F10 murine melanoma cells of high metastatic ability were cotransfected with a 265 base pair
cDNA containing the leader sequence of the human preprourokinase gene in an antisense direction (plasmid pSV2-ASuPA) and pSV2-neo. Two of the antisense clones secreted approximately 70% of the urokinase activity of control cells. Southern blot hybridization analysis confirmed the incorporation of pSV2-ASuPA into the genomic DNA. In the lung colonization assay, the cells containing antisense urokinase cDNA showed a 40 to 42% decrease in the ability to form lung tumors. These results support the conclusion that urokinase is an important promoter of the extravasation step in tumor cell metastasis. It was also observed that the majority of tumors from the control mice (injected with pSV2-neo transfected cells) were smaller than those of the experimental mice (injected with pSV2-neo and pSV2-ASuPA transfected cells). This result indicates that inhibition of urokinase production may decrease the metastatic potential and correspondingly increase the tumorigenic potential of murine melanoma cells.
REFERENCES


D. Belin, F. Godeau, and J.D. Vassalli. 1984. Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content. EMBO J., 3, 1901-1906.


I.A. Ramshaw, P. Badenoch-Jones, A. Grant, M. Maxted, and C. Claudianos. 1986. Enhanced plasminogen activator production by highly metastatic variant cell lines of rat mammary adenocarcinoma. Invasion Metastasis, 6, 133-144.


APPENDIX
Prior to the use of pSV2 expression vector pSV2-uPA (shown in Figure 3), the plasmid pRdzbuktt (shown in Figure 1) which contains Rous sarcoma virus (RSV) long terminal repeats (LTR) promoter was tested for the preprourokinase gene expression. The expression vector containing RSV LTR promoter had been previously used in a variety of murine cell lines other than Bl6 cell lines (Gorman et al., 1982). B16-F1 cells were cotransfected with pSV2-neo and pRdzbuktt, shocked with glycerol, and grown in the presence of Geneticin as described previously. The DNAs were prepared from the surviving cells of pSV2-neo and pRdzbuktt transfected or pSV2-neo transfected cells. To detect the pSV2-neo incorporation, DNAs were digested with HindIII, or double digested with HindIII/BamHI or HindIII/PstI, separated by electrophoresis, transferred to nitrocellulose filter, and probed with $^{32}$P-labeled pSV2-neo fragment. The digestion of pSV2-neo with HindIII generates one single DNA band of 5729 base pairs and $^{32}$P-labeled probe hybridizes with the
band. The double digestion of pSV2-neo with HindIII and BamHI generates two DNA bands with base pairs of 3386 and 2346 and the probe hybridizes with the 2346 band. The double digestion of pSV2-neo with HindIII and PstI generates five DNA bands with base pairs of 1883, 1430, 958, 923, and 535 and the probe hybridizes with the 1430 and 923 bands. Figure 24 shows that the cells transfected with pSV2-neo alone or cotransfected with pSV2-neo and pRdzbuhtt demonstrate the restriction endonuclease digested bands identical to those of pSV2-neo plasmid.

To detect the pRdzbuhtt incorporation, Southern blot hybridization assay was performed using the $^{32}$P-labeled SacI and HindIII fragment of pRdzbuhtt as a probe. However, in Figure 25, Southern blot hybridization assay failed to show pRdzbuhtt incorporation to the genomic DNA of the transfected cells. The production of plasminogen activator by the pRdzbuhtt transfected cells was determined by the fluorogenic substrate assay and compared to pSV2-neo transfected or untransfected cells. As shown in Table 15, the cells transfected with pRdzbuhtt produced same amounts of plasminogen activator as pSV2-neo transfected or B16-F1 cells. Taking Figure 25 and Table 15 together, the results show that the plasmid pRdzbuhtt was not incorporated into the genomic DNA of B16-F1 cells,
Figure 24. Southern blot analysis of DNA isolated from pSV2-neo and pRdzbuktt transfected cells to detect the pSV2-neo incorporation

DNAs were isolated from pSV2-neo transfected or pRdzbuktt transfected B16-F1 cells. The DNAs (10 ug) were cleaved with HindIII or double digested with HindIII and BamHI or HindIII and PstI and electrophoresed through 0.8% agarose gel. A control pSV2-neo plasmid preparation was similarly digested with the same enzymes. The DNAs were transferred to nitrocellulose and probed with $^{32}$P-labeled PvuII fragment of pSV2-neo. Lanes 1,2,3 contain DNA made from the plasmid pSV2-neo, lanes 4,5,6 contain DNA made from pSV2-neo transfected cells, and lanes 7,8,9 contain DNAs made from the pSV2-neo and pRdzbuktt transfected cells. DNAs in lanes 1,4,7 were digested with HindIII, DNAs in lanes 2,5,8 were double digested with HindIII and BamHI, and DNAs in lanes 3,6,9 were double digested with HindIII and PstI.
m.w. marker

<table>
<thead>
<tr>
<th></th>
<th>pSV2-neo</th>
<th>TF-pSV2-neo</th>
<th>TF-pRdzbuett and pSV2-neo</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>H+P</td>
<td>H+P</td>
<td>H+P</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>4.36</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>186</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 25. Southern blot analysis of DNA isolated from pSV2-neo and pRdzbuukt transfected cells to detect the pRdzbuukt incorporation

DNAs were isolated from pSV2-neo transfected or pRdzbuukt transfected B16-F1 cells. The DNAs (10 ug) were cleaved with HindIII or double digested with HindIII and SacI or HindIII and PstI and electrophoresed through 0.8% agarose gel. A control pRdzbuukt plasmid preparation was similarly digested with the same enzymes. The DNAs were transferred to nitrocellulose and probed with $^{32}$P-labeled HindIII-PstI fragment of pRdzbuukt. Lanes 1,2,3 contain DNA made from the plasmid pRdzbuukt, lanes 4,5,6 contain DNA made from pSV2-neo transfected cells, and lanes 7,8,9 contain DNAs made from the pSV2-neo and pRdzbuukt transfected cells. DNAs in lanes 1,4,7 were digested with HindIII, DNAs in lanes 2,5,8 were double digested with HindIII and SacI, and DNAs in lanes 3,6,9 were double digested with HindIII and PstI.
<table>
<thead>
<tr>
<th>m.w. marker</th>
<th>pRdzbktt H H+S H+P</th>
<th>TF-pSV2-neo H H+S H+P</th>
<th>TF-pRdzbktt and pSV2-neo H H+S H+P</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.56 --</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.36 --</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.32 --</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.03 --</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 2 3 4 5 6 7 8 9
Table 15. Quantification of plasminogen activator (PA) production by B16-F1, B16-F10, and transfected B16-F1 cells with pSV2-neo or pRDzbuKtt as determined by fluorogenic substrate assay

<table>
<thead>
<tr>
<th>Cell</th>
<th>PA activity (Mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16-F1</td>
<td>0.57 ± 0.09&lt;sup&gt;c,d,e&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F1 (pSV2-neo)</td>
<td>0.56 ± 0.13&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F1 (pRDzbuKtt)</td>
<td>0.51 ± 0.07&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>B16-F10</td>
<td>1.38 ± 0.10&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>B16-F1, B16-F10, and B16-F1 transfected cells with pSV2-neo or pRDzbuKtt were incubated with fluorogenic substrate for plasminogen activator, methoxy succinyl-L-Gly-L-Gly-L-Arg-7-amino-4-methylcoumarin HCl. The ability of plasminogen activator to release 7-amino-4-methylcoumarin (AMC) from the substrate was measured.

<sup>b</sup>Plasminogen activator activity is expressed by the slope of linear release of AMC under the assay conditions.

<sup>c</sup>Not significantly different (p = 0.92)

<sup>d</sup>Not significantly different (p = 0.31)

<sup>e</sup>Significantly different (p = 0.00)
which subsequently failed to produce human urokinase.

Another attempt was made to express the human preprourokinase gene by the plasmid, pCLH3AXBPV, which contains bovine papilloma virus (BPV-1) with MT-1 (metallothreonine) promoter (Figure 4). The insertion of human preprourokinase gene into the pCLH3AXBPV is shown in Figure 5 and the final plasmid structure, pCLH3AXBPV-uPA, is shown in Figure 6. The plasmid was similarly transfected to Bl6-F1 cells and a fibrin overlay assay was performed. The fibrin overlay assay tests the transient expression of urokinase gene prior to its incorporation to the genomic DNA. The optimum condition for the assay was developed for Cl27 cells (mammary tumor cell line of an RIII mouse obtained from American Tissue Culture Center, No. CRL1616) transfected with pCLH3AXBPV-uPA as described by Reddy et al. (1987). The results in Figure 26 demonstrate the absence of plasminogen activator activity in the fibrin agarose matrix which indicates the cells transfected with plasmid pCLH3AXBPV-uPA did not produce urokinase. In contrast, Cl27 cells transfected with pCLH3AXBPV-uPA gave positive results with respect to pSV2-neo transfected controls (data not shown).

The efficiency of gene transfer under the control of the viral regulatory sequence might have limitations.
Figure 26. Fibrin overlay assay to detect the transient expression of urokinase gene by the transfection of the plasmid pCLH3XBPV-uPA to B16-F1 cells

B16-F1 cells transfected with pCLH3AXBPV-uPA were mixed with agarose in MEM supplemented with 10% heat inactivated FBS containing fibrinogen and thrombin and incubated at 37°C overnight. The ability of plasmin, which was activated from plasminogen by the urokinase, was detected by the clearing zones of fibrin degradations on the agarose matrix. Plasminogen was supplied from the FBS in the reaction mixture and fibrinogen was activated to fibrin by thrombin. The cells transfected with pCLH3AXBPV-uPA shows the absence of clearing zones which indicate that the cells did not produce urokinase (top). A control which contained several drops of urokinase solution showed clearing circles of fibrin degradation (bottom).
which affect the rate of ions to increase with time. For example, it is known that the rate of ion-terminal in foreign gene expression may be increased by inserting foreign gene expression into the terminal.
which affect its application to certain cell lines. For example, it has been suggested that the flanking long terminal repeats (LTRs) as well as BPV vectors may interfere with transcriptional regulation of the inserted foreign gene sequences that could lead to a lack of expression in certain cell lines (Howard, 1983).
The dissertation submitted by Heron Yu Cook has been read and approved by the following committee:

Richard M. Schultz, Ph.D.; Director
Professor and Chairman of Biochemistry
Loyola University of Chicago

Allen Frankfater, Ph.D.
Associate Professor of Biochemistry
Loyola University of Chicago

Mark R. Kelley, Ph.D.
Assistant Professor of Biochemistry
Loyola University of Chicago

Simone Silberman, M.D.
Professor of Pathology
Loyola University of Chicago

Klaus E. Kuettner, Ph.D.
Professor and Chairman of Biochemistry
Rush University

The final copies have been examined by the director of the dissertation and the signature which appears below verifies the fact that any necessary changes have been incorporated and that the dissertation is now given final approval by the Committee with reference to content and form.

The dissertation is therefore accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

4/14/80

Date

Director’s signature